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2  Abstract 
Introduction 
Homeopathic treatment has a long tradition. Because of its widespread use as alternative therapy 
in Norway and Europe, but also in nations such as India, investigation into patient safety related 
to homeopathic treatment is important. Risk in homeopathy can be divided into direct and 
indirect risk. Direct risk is directly linked to the intervention itself while indirect risk is related to 
the setting effects, such as e.g. the practitioner, rather than to the homeopathic remedy. 
Homeopathic aggravation, a concept specific for homeopathy, may impose a particular risk as it 
allows the health status of the patient to deteriorate before there is an improvement. In 
homeopathic theory, such a temporary deterioration is seen as being a part of the healing process. 
Aims 
In this research plan, adverse effect was understood as all diseases or unwanted and/or harmful 
reactions appearing during a study period, regardless of their relation to the actual treatment. The 
term encompasses all unwanted effects, without making assumptions about their mechanisms. It 
thus avoids ambiguity and the risk of misclassification. 
The aim was to explore and provide more knowledge about patient safety in homeopathy. With 
regard to safety, particular emphasis was placed on the concept of homeopathic aggravation.  
Materials and Methods 
A mixed method approach combining qualitative and quantitative methods was used, including 
four focus group interviews, a cross-sectional survey, a systematic review, and a meta-analysis. 
Results 
Initial steps were taken towards development of guidelines for the assessment of risk in 
homeopathy. The results suggest that both lay as well as medical homeopaths assessed the patient 
risk precisely according to the guidelines developed in this research project. Adverse effects as 
well as homeopathic aggravations were reported by patients after homeopathic treatment. 
According to the CTCAE criteria, these events were mild to moderate and transient. According to 
the systematic review and meta-analysis included in this research plan, direct risk related to the 
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homeopathic remedy was found to be minor and moderate, apart from five cases of homeopathic 
aggravations that were graded as serious. The meta-analysis suggested that adverse effects were 
reported to a similar degree in the homeopathy compared to the placebo groups. 
Conclusion 
According to the systematic review and cross-sectional study included in this research plan, 
homeopathic treatment is generally associated with low to moderate direct risk related to the 
remedy. Indirect risk, however, is associated with homeopathic practice where the concept of 
homeopathic aggravations imposes a particular risk. To control for indirect risk and improve 
patient safety, it is important to distinguish between homeopathic aggravations and adverse 
effects within homeopathic theory. Criteria to distinguish these two concepts must, however, be 
acceptable to homeopaths and applicable in everyday practice. Furthermore, it allows comparison 
of safety data across studies on homeopathy. A reporting system for adverse effects in 
homeopathy should include criteria to distinguish these two concepts, among others, which 
enables homeopaths to apply this reporting system. Moreover, severity and duration of both 
homeopathic aggravations and adverse effects need to be classified within the same grading 
system. The criteria developed in the research plan presented here were tested and found relevant 
for safety purposes. In addition, it turned out that high medical and homeopathic skills are 
required to assess patient risk accordingly, which is heavily dependent on homeopathic training 
and education. Consequently, there is considerable potential for risk related to homeopathic 
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8 Definitions of terminology used in the thesis 
Adverse drug event is harm caused by the use of a drug. In common practice it may be defined 
as harm caused by a drug or the inappropriate use of a drug. 
Adverse drug reaction is an appreciably harmful or unpleasant reaction, resulting from an 
intervention related to the use of a medicinal product. The reaction predicts hazards regarding 
future administration and warrant prevention or specific treatment, or alteration of the dosage 
regimen, or withdrawal of the product. 
Adverse effect is understood as all diseases or unwanted and/or harmful reactions resulting from 
a medication or an intervention, regardless of their relation to the actual treatment. 
Adverse event is any unfavorable and unintended signs (including an abnormal laboratory 
finding), symptom, or disease temporarily associated with the use of a medical treatment or 
procedure that may or may not be considered related to the medical treatment or procedure.  
Adverse event is an incident (event, circumstance, complaint and loss) in which a person 
receiving health care is harmed. Event is understood as something that happens to or with a 
person. 
Adverse reactions are present when the right drug was administered for the correct indication, in 
the proper dose, by the right route, yet still the patient develops an unwanted symptom, suffers 
unexpectedly, and is exposed to unpreventable harm. Adverse reactions may also result from 
some diagnostic tests, therapeutic interventions or devices. 
Alternative treatment (CAM) is primarily understood as health-related interventions practiced 
outside the official health care system by unauthorized health personnel. Moreover, treatment 
practiced within the official health services or by authorized health personnel is also covered by 
the term alternative treatment if the methods are essentially used outside the established health 
services.  
Homeopathy/homeopathic treatment is everything a homeopath does in the consultation, from 
prescribing homeopathic remedies to giving other kinds of alternative treatment and lifestyle 
advice. An important element of the therapy is the particular interaction between the patient and 
the homeopath due to long consultation times. 
Homeopathic aggravation is a temporary worsening of existing symptoms following the 
administration of a correctly chosen homeopathic prescription, which is expected to be followed 
by an improvement. 
Classical homeopathy is a system of medicine using substances whose effects, when 




Medical error is commonly defined as any preventable event that may cause or lead to 
inappropriate medication use or patient harm while the medication is in control of the health care 
professionals, patients or consumers. 
Nocebo is the development of negative effects that are attributed to a medication, albeit the drug 
itself does not cause the provocation of these symptoms. 
Placebo is a harmless pill, medicine, or procedure prescribed more for the psychological benefit 
to the patient than for any physiological effect. The placebo effect refers to any improvement of 
the condition of an individual who has received a placebo treatment. It is assumed that, if the 
placebo had not been given, no such improvement would have been observed. In contrast, 
placebo response refers to the change in an individual caused by a placebo manipulation. 
Patient safety is the reduction of risk of unnecessary harm associated with health care to an 
acceptable minimum, understood as preventing and limiting unfortunate consequences or 
damages due to any health treatment. 
Risk is a compound measure of the probability of an event, and the magnitude and impact of its 
potentially negative outcome of that event. 
Direct risk is related to the intervention, e.g., harm caused by pharmacological products, medical 
treatments and procedures. 
Indirect risk is related to the setting effects, such as the practitioner rather than to the medicine. 
For example, a practitioner with limited medical and homeopathic skills may overlook serious 
symptoms and thereby cause a delay in necessary conventional treatment. 
Side effect is an effect produced by an agent, other than that intended. 




9  Introduction 
9.1 The principles of patients’ rights and patient safety 
Patient safety in homeopathy was the main focus in the research plan presented in this thesis. 
Historically, risk and patient safety have been considered essential in treatment since the time of 
Hippocrates and the dictum to do no harm has been imperative (1). With the dramatic advance of 
the medical profession over the last fifty years, the topic has received considerable attention, in 
particular with the introduction of “The Nuremberg Code” (2), and the Helsinki declaration 
(1964/2004) in medical research. 
A severe example from homeopathic treatment in which the ethical dictum to do no harm was 
heavily violated, was a case where a 9 month old baby was admitted to hospital after 
homeopathic treatment (3). She had been given several homeopathic remedies to treat atopic 
dermatitis. The child developed Bullous Pemphigoid during the treatment period, which lasted 
for five months. When the baby was finally admitted to hospital, its condition was life 
threatening. This severe situation occurred because the homeopath interpreted the worsening of 
symptoms as homeopathic aggravations and continued treatment instead of referring the baby to 
conventional care (figure 9-1). This case illustrates that even though homeopathy is regarded by 
many as a non-effective and harmless intervention, homeopathic practice, even though many 
patients utilize it with high satisfaction (4, 5), may not be entirely risk free. 
Homeopathy was established and developed in Germany in the late 18th century by Samuel 
Hahnemann. Classical homeopathy is “a system of medicine using preparations of substances 
whose effects, when administrated to healthy subjects, correspond to the manifestations of the 
disorder in the individual patients” (6). The practice of homeopathy involves the selection and 
prescription of a single remedy that is prescribed in a dosage expected to improve the patient’s 
symptoms. As the mechanisms of the action of homeopathic remedies remain unclear, this form 
of treatment is controversial and considered to lack evidence. 
Homeopathy in the context of this dissertation is understood as everything a homeopath does in 
the homeopathic consultation, from prescribing homeopathic remedies to giving other kinds of 
alternative treatment and life style advice. An important element of the intervention is the 
particular interaction between the patient and the homeopath. As a general rule, patients 
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consulting homeopaths often receive additional advice on life style issues. Some of them may be 
related to the homeopathic theory, e.g., not to drink coffee. Other types of advice are usually 
based on the knowledge of the individual homeopath. Moreover, most homeopaths expect a 
certain degree of worsening in the symptoms throughout the intervention, meaning that the health 
status will deteriorate before improving, and inform their patients about this expectation. This 
expectation relates to the concept of homeopathic aggravation which is a part of homeopathic 
theory and describes a temporary deterioration of the patient’s health status, followed by an 
improvement (7) (For further discussion see section 11.4). 
 
Figure 9-1 Baby with generalized tense blisters, erosions, and crusts. Lesions also affect the face, hands 
and feet. (A) Note the lack of subcutaneous fat and sign of dehydrations, with skin hanging in loose folds 
and the abdomen and trunk. Close-up view of the lesions on the (B) left hand and (C) right leg. 
Basically, four ethical rules are fundamental with regard to patients’ rights: 1) Non-maleficence 
or the duty not to harm patients, meaning that the harm should not be disproportionate to the 
benefits of treatment, is one of Beauchamp and Childress’ widely accepted four major ethical 
principles in the medical profession (8). 2) Beneficence, understood as the importance of 
balancing the benefits of treatment against the risks and costs. 3) Respect for autonomy, 
emphasising the significance of respecting the decision-making capacities of autonomous 
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persons. This principle enables individuals to make reasoned, informed choices. 4) Justice, 
expressing a fair distribution of benefits, risks and costs, and the idea and concept that patients in 
similar situations should be treated in a similar manner. 
To avoid unnecessary risk to patients during treatment is therefore a basic ethical principle and 
the operationalization of that principle is to ensure patient safety. With regard to this research 
plan, two definitions of patient safety were regarded as appropriate: Patient safety was 
understood as the reduction of risk of unnecessary harm associated with health care to an 
acceptable minimum (9). Furthermore, the definition by Aase et al (10) who define patient safety as 
preventing and limiting unfortunate consequences or damages due to any health treatment was 
considered essential. 
Operationally and methodologically, risk is generally defined as a compound measurement of the 
probability of an event and the magnitude of the potential negative outcome of that event (11). 
Risk can be assessed from a variety of perspectives. In medical science risk can be divided into 
direct and indirect risk as illustrated in figure 9-2. Direct risk is caused by the treatment itself and 
related directly to the intervention, while indirect risk is related to the setting effects, such as e.g., 
the practitioner rather than to the medicine (12). For example, a practitioner with limited medical 
and homeopathic skills may overlook serious symptoms and, thereby, cause a delay in necessary 
conventional treatment, which is risky for the patient. A harmful reaction implying risk to patient 
safety is usually named “adverse effects” (13). 
 
 
Figure 9-2 Understanding of patient safety and risk in this research plan. Direct risk is caused by the 
treatment itself and related directly to the intervention, while indirect risk is related to the setting 
effects, such as e.g. the practitioner, rather than the medicine. 
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9.2 Homeopathy as CAM treatment in Norway 
In the research plan presented here alternative treatment (also named Complementary and 
Alternative Medicine- CAM) is primarily understood as health-related interventions practiced 
outside the official health care system by unauthorized health personnel (14). Moreover, treatment 
practiced within the official health services or by authorized health personnel is also covered by 
the term alternative treatment if the methods are essentially used outside the established health 
services. For example, if an acupuncturist offers acupuncture at a private clinic she or he is an 
alternative practitioner. If a physiotherapist practices acupuncture inside a hospital, the treatment 
is defined as alternative treatment delivered as a part of her or his appointment as a 
physiotherapist. 
As a general rule, therapies out of the spectrum of CAM are generally offered outside the 
National Health Care System in Norway, which may in itself be a risk to patient safety. 
Moreover, CAM therapies are usually derived from traditional systems of medicine (15), with little 
or no research tradition. Therefore there is often limited knowledge about efficacy, effectiveness, 
biological mechanisms, and safety issues and patient safety is a central and yet a widely 
unresolved issue in CAM. Consequently, the National Research Centre in Alternative and 
Complementary Medicine (NAFKAM) developed a research strategy with particular focus on 
patient safety (16). 
Homeopathic practices are vaguely regulated in Europe and in Norway. Anyone, irrespective of 
training and regulation, can call himself or herself a homeopath. Consequently, homeopaths 
without appropriate medical and homeopathic training may fail to see and identify a severe health 
condition of the patient and may continue homeopathic treatment, even when conventional 
treatment should be imperative (17). 
On the background of the current legal situation in Norway, the investigation of patient safety in 
CAM generally, and in homeopathy in particular is of primary importance. From the health 
authorities’ point of view, it is of interest to know to what extent the therapy is used in society 
and to gather information about the likelihood of harm to patients when using it. From the 
patients’ point of view, it is of high relevance to know whether the therapy is safe to use and 
whether it will help to improve health and/or reduce the symptoms. Therefore, similar to General 
Practitioners (GP), homeopaths are confronted with various kinds of conditions, from minor 
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complaints to severe, acute or chronic diseases. In order to ensure patient safety under these 
conditions, it is mandatory that homeopaths have medical knowledge not only about the 
limitation of the intervention itself, but also about the unfavourable effects that the treatment may 
cause in certain situations. Consequently, the Norwegian Parliament (The Storting) (18) requested 
differentiation between qualified and unqualified practitioners of alternative medicine. (Refer to 
the Norwegian Parliament’s unanimous resolution in processing their parliamentary report “St. 
m. 50 1993-4 Samarbeid og styring”.) The research plan presented here will focus exclusively on 
the risks to patient safety associated with homeopathic practice. 
Within the framework of physiological and pharmacological knowledge, there is no plausible 
mechanism of actions for homeopathic remedies of high dilutions, since they are ultra-molecular 
and no molecule of the original substance is left in the remedy. This is one of the major reasons 
why homeopathy is rather controversial within the medical profession, and claimed treatment 
effects are commonly attributed to unspecific mechanisms or interpreted as pure psychological or 
placebo effects (19). Homeopathy is mostly controversial because, in this context, the remedy can 
be seen as a ritual of administering treatment and as such a part of the interaction between the 
patient, practitioner, and treatment environment. In such an interpretation, the healing would be a 
result of the clinical encounter (20). Considering the long consultation time the homeopaths offer 
their patients, and the intensity of the homeopathic anamnesis, it must be acknowledged that a 
placebo effect induced through increased attention is likely to play a relevant role in homeopathic 
treatment. However, a powerful effect as the placebo effect may also include aspects of harm to 
the patients, namely, if a nocebo effect is induced (21). 
9.3 Risk in medicine 
9.3.1 What is risk? 
Risk management in health care can be understood as designing and implementing a program of 
activities in order to identify and avoid or minimize risk to patients, employees, visitors, and 
institutions (22). In order to achieve these goals, an operational definition of risk is mandatory. 
With regard to medical interventions, any pharmacological substance capable of producing a 
therapeutic effect can also produce unwanted or adverse effects. This holds true even for placebo 
and nocebo effects (for discussion see section 11.3.1). The risk related to these effects ranges 
from close to zero (for example the use of Nystatin) to high (the use of antineoplastic drugs) (23). 
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Studies indicate that adverse events occur almost daily in medium-sized hospitals or outpatient 
panels (24). Findings from Denmark (25), New Zealand (26), and Canada (27) suggest a relatively 
high rate of 10% adverse events (28). 
Under the code of medical ethics, physicians are obligated to report adverse effects. However, 
voluntary reporting is often neglected and there are no individual consequences for not reporting 
adverse effects. Thus, the extent of underreporting remains unknown (29). Studies have shown that 
there is a tendency in the medical literature to underreport adverse effects in medicine. According 
to Venulit (30), only 21% of 1379 publications in conventional medicine contained adequate 
information to determine causality regarding adverse effects, most of which did not include 
sufficient information to interpret the clinical significance of adverse effects. A recent study 
confirmed these findings (31). 
9.3.2 Different forms of risk 
In order to enable inclusion of as many risk aspects as possible, risk was defined broadly in the 
research plan presented here. As already pointed out, risk in this context is understood as a threat 
to patient safety and can be divided into direct and indirect risk (see figure 8-2). 
It is likely that most simple “direct risks” (at least on a theoretical basis) are related to the 
intervention, e.g. such as harm caused by pharmacological products, medical treatments and 
procedures. Several terms are used to describe direct risk, such as adverse effects or adverse 
reactions, and adverse drug reactions. Moreover, numerous terms are used to describe adverse 
effects such as adverse reactions, adverse drug reactions and adverse events (9). In a survey 14 
definitions were found for “adverse events”, 16 for “medical errors”, and five for “adverse drug 
events” (9, 22). These differences in definitions and the broadness of the contexts illustrate that risk 
in relation to a medical intervention is a complex problem and thus difficult to operationalize due 
to the inconsistent use of terminology. 
In order to understand the complexity of the risk phenomenon, it is useful to elucidate the topic 
from different angles. Therefore, the following chapter will introduce several definitions of risk, 
which usually relate to different sources of risk and various conditions of its occurrence (the 




Table 9-1 Descriptors of risk grouped according to sources and concepts of risk. 
Risk Concept Sources of risk Descriptors/Origin 
Direct  and indirect risk Medical error (see section 9.3.2.1) Human resources 
Direct risk Direct drug reaction (see section 
9.3.2.2) 
Adverse event 
Adverse drug reaction 
Adverse drug event  
Side effect 





 Medical error 9.3.2.1
A medical error (32) may occur from incorrect actions (commission) or failure to perform proper 
actions (omission) (22). Fortunately, the chance of a serious mistake occurring during any given 
medical procedure is small, but these errors happen. Philadelphia News reported several case 
histories about medical errors. One case involved a doctor performing brain surgery on the wrong 
side of a patient's head and another patient died after he had received an intravenous solution 
containing heparin (a blood thinner), 11 times the prescribed dose (33). Such events may be related 
to professional practice, health care products, procedures and systems, including prescriptions, 
order communications, product labeling, packing and nomenclature, dispensing, distribution, 
administration, education monitoring and use. Some authors estimate that less than 1% of 
medical errors result in harm (34). 
 Direct drug reaction 9.3.2.2
A common term describing risk associated with direct drug action is adverse event (9, 35-37). It is 
recommended that the term adverse event is used in order to describe harmful events occurring 
during a trial (35, 38). An adverse drug reaction is an appreciably harmful or unpleasant reaction, 
resulting from an intervention related to the use of a medicinal product. The reaction predicts 
hazards with regard to future administration and warrant prevention or specific treatment, or 
alteration of the dosage regimen, or withdrawal of the product (23). Consequently, an adverse drug 
reaction is an adverse event with a causal link to a drug (32). An adverse drug event (39), however, 
is understood as harm caused by a drug or the inappropriate use of a drug (32). 
When classifying adverse drug events, the first step is to find possible relations between the 
unwanted events and the medicinal products (including over-the-counter formulations, herbal and 
traditional remedies, recreational drugs or drugs of abuse). The next step is to determine possible 
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relations to the medication. In cases of patients taking several medicines, determining possible 
causative relations might be challenging. The problem is complex, since the cause of patients’ 
complaints may be related to other, concomitant diseases, or one or more drugs or interactions 
between drugs. Therefore, the application of formal methods to assess the probability of cause 
related to a suspected drug event is common (40). 
A side effect is an effect produced by an agent, other than that intended (22). However, this 
definition has been criticized since it is quite related to the immediate drug reaction and may 
therefore be interpreted as minimizing the potential hazard of the pharmacological product 
(agent). All of the above-described definitions are closely related to drug or pharmacological 
effects (direct risk). These definitions are useful when investigating or documenting direct risk, 
but they may underestimate the total risk of an intervention, since they exclude unwanted effects 
that are related to other aspects of the interventions (indirect risk). The following paragraph 
introduces a number of definitions that go beyond the immediate drug related phenomena, even 
though they include them. 
 Broader definitions of risk 9.3.2.3
An adverse reaction is a broader definition of risk as it includes response to a drug which is 
noxious and unintended and which occurs at doses normally used in man for the prophylaxis, 
diagnosis, or therapy of disease, or for the modification of physiological function (22, 37).  
 In surveillance, the primary aims are to monitor the incidence or prevalence of specific health 
problems, to document their effects in defined populations, and to identify people and those at the 
greatest risk. The detection of an increase in health problems should alert health agencies and 
induce further investigation (41). Surveillance represents in this sense more a methodology than 
definitions. It is, however, interesting with regard to risk assessment, since it intends to explicitly 
monitor risk comprehensively and thus includes more sources of risk than merely those related to 
drugs. 
Adverse effect (42), is quite similar to adverse event. However, an adverse effect is an adverse 
outcome that can be attributed to some action of a drug or an intervention, while an adverse event 
is a harmful event that occurs while a patient is taking a drug, for example during a trial. The 
term “adverse effect” encompasses all unwanted effects, without making assumptions about their 
mechanisms. Thus, adverse effect avoids ambiguity and the risk of misclassification (23). 
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Therefore, adverse effect covers, similar to surveillance, a broad spectrum of potential risks and 
thus includes more sources of risk than merely those related to drugs. However, compared to 
surveillance, the connection to the operational methodology is not as close. 
9.3.3 “Adverse effects” as an operational definition of risk 
A broader definition of risk is more appropriate in complex treatment situations, e.g. in 
rehabilitation or complex lifestyle oriented intervention programs. Such programs may be found 
in cardiology or diabetes care, where other interventions such as nutrition or physical exercise 
play a significant role besides appropriate medication. 
The homeopathic intervention is a complex treatment situation that consists of in-depth 
consultations often reaching beyond the bodily complaints and that involves psychological 
problems. Moreover, this kind of intervention is generally combined with lifestyle advice. 
Consequently, a broader definition of risk is needed (see figure 9-3). Therefore, the term “adverse 
effect” that encompasses all unwanted effects, without making assumptions about their 
mechanisms is suitable for complex treatment situations like homeopathy. 
 
Figure 9-3 “Adverse effect” covers a broad spectrum of potential risks and thus includes more sources of 
risk than merely those related to drugs, and is therefore suitable for this research plan. This figure 
illustrates risk concepts categorized according to direct and indirect risk. 
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The nocebo effect is development of negative effects that are attributed to a medication, even 
though the drug itself does not cause the provocation of these symptoms. The iceberg model is a 
model of missed diagnosis. These potential risks will be further discussed later in the thesis (see 
section 11.4). 
9.4 Risk in homeopathy 
9.4.1 Utilization, theory and practice of homeopathy 
Homeopathy is a popular treatment modality in Europe. The CAMbrella report found that 
homeopathy was used by 15% of the Europeans seeking CAM treatment (43). The most recent 
Norwegian study, conducted in November 2012, stated that 46% of the adult population had 
reported use of CAM during the previous 12 months. Thirty-seven percent had seen a CAM 
practitioner. The use of homeopathy was reported by 3% (44). 
As mentioned earlier, homeopathy is not a part of the official health care system in Norway. The 
profession is vaguely regulated by the law of alternative therapies (14), which enables all citizens 
to legally treat patients as long as they cause no harm. Therefore, anyone can call himself/herself 
a homeopath regardless of education or training in homeopathy. The legal situation for 
homeopaths in Europe is mostly similar to Norway, with the exception of Switzerland, Latvia and 
Liechtenstein that have regulations of the profession as well as the treatment (45). Overall, 21 
countries have vague regulations of the profession such as Norway, whereas 14 countries have no 
regulation of the profession or treatment (45). 
Norway has a governmentally established registry for alternative practitioners. The registration is 
voluntary, but a membership allows the homeopaths to use the designation “registered” as 
supplement to their professional title. In order to obtain membership in the registry 
(Brønnøysundregisteret for alternative behandlere) the practitioner must prove to be a member of 
a professional association of practitioners, which has been granted official recognition from the 
registry. The purpose of the registry is i) to contribute to patient safety and consumers’ rights and 
ii) to enhance professionalism among registered alternative practitioners. However, there are no 
requirements regarding medical or homeopathic education for the practitioners in order to obtain 
membership in the registry. Moreover, there are only few physicians certified as homeopaths 
(medical homeopaths). Among the 1,151 Norwegian physicians who participated in a survey in 
1997, only 46 practiced homeopathy (46). 
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According to homeopathic theory, the development of homeopathic remedies is based on two 
principles: і) the Law of Similiaris (similia similibus curentur), meaning “like cures like” and іі) 
individualization (7, 47). The hypothesis of the Law of Similiaris implies that substances capable of 
causing certain symptoms in healthy subjects can be used as medicines to treat people suffering 
from similar symptoms. Homeopathic medicines undergo a process of a stepwise dilution and 
vigorous shaking, until the content of the substance to be diluted is very low or non-existent in 
the solvent (alcohol, milk, sugar, or other) (48, 49). Avogadro’s number (6.023 x 1023) is the 
threshold, indicating that no molecule of the original substance is left in the remedy. Such diluted 
remedies, which no longer include substrate, are called ultra-molecular (48). Homeopaths believe 
that information passes from the diluted agent to the solvent during the dilution process, which in 
light of current knowledge of physics is implausible. Since these remedies do not contain any 
active substances in a chemical or pharmacological sense, they could also be seen as pure 
placebos. Pure placebos, such as sugar tablets and saline injections (50) are inert treatment. From 
this perspective, homeopathy could be considered a pseudo-therapy. 
However, not all homeopathic remedies are ultra-molecular. Many are low dilutions (D6 or D12). 
These remedies still contain a substantial number of molecules. Therefore, a direct 
pharmacological effect of the remedy in low dilutions is principally possible, whereas this is 
impossible for remedies of high dilutions. 
In conclusion, while low dilutions may induce direct risk, any risk related to the administration of 
remedies of high dilutions must, according to current scientific knowledge, be related to indirect 
risk. Nonetheless, many patients report substantial benefits from homeopathic treatment (4, 51), 
even though ultra-molecular homeopathic remedies cannot be associated with pharmacological 
effects. Therefore, the homeopathic treatment with regard to ultra-molecular remedies may work 
via psychological mechanisms such as the placebo effect (19). Like in all forms of medicine, it is 
equally important to establish a good relationship with the patients in order to understand and 
interpret the patients’ symptoms. The particular intensity and duration of the homeopathic 
consultations may thus be advantageous for the treatment (7). 
9.4.2 Risk profile for homeopathic remedies 
Homeopathic remedies are mostly considered harmless in terms of safety concerns. However, 
some aspects of the production of homeopathic medicines might constitute potential safety 
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hazards. Firstly, not all homeopathic medicines administered are of high dilutions and remedies 
in low dilutions may cause harm if administrated too frequently over a long period of time. If a 
homeopathic remedy made from a mother tincture is administered in its most concentrated form, 
it may cause direct harm if the patient is sensitive to the source material (6). Secondly, 
homeopathic medicines are produced from a wide range of natural or synthetic sources such as 
minerals and chemicals, as well as plant materials, including roots, stems, leaves, flowers, bark, 
pollen, lichen, moss, ferns and algae; microorganisms, including fungi, bacteria, viruses and plant 
parasites; animal organs, tissues, secretions, and cell lines. Human materials may include tissues, 
secretions, hormones, and cell lines. Some of these source materials constitute potential safety 
hazards, since all materials of animal or human origin may contain pathogenic agents (6). Thus, it 
is vital to ensure high quality on the source materials and the excipients applied in the 
manufacture of homeopathic medicines to avoid risky situations. Failure of good manufacturing 
practice may result in major quality and safety concerns such as misidentification, impurity of 
starting material, cross-contamination or incidental contamination (6). 
In the European Union homeopathic medicines are legally termed homeopathic medicinal 
products, and consist of medicines with a botanical, chemical, mineral or zoological origin (54). 
Homeopathic medicinal products are subject to the same requirements as other medicinal 
products regarding manufacturing procedures, technical quality, and all other requirements with 
the possible exception of documentation of efficacy (52). Thus, registration or marketing 
authorization for homeopathic medicinal products is always granted at the national level. In 
Norway homeopathic medicines are classified as medicinal products. Normally all medicines 
require separate marketing permissions from the Norwegian Medicines Agency. However, 
homeopathic medicines are exempted from these requirements and may be sold as long as the 
country of production (inside the EU) has granted permission for marketing (53). Most 
homeopathic medicines can be bought without prescriptions. The directive 2001/83/EC of the 
European Parliament and of the Council of 6 November, 2001 on the Community code relating to 
medicinal products for human use states that “no medicinal product may be placed on the market 
of a member state unless a marketing authorization has been issued by the competent authorities 
of that member state in accordance with this delivery or an authorization has been granted in 
accordance with Regulation (EEC) No 2309/93” (53). 
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Adverse effects of homeopathic remedies have been investigated by Dantas and Rampes (54). 
They stated that there was a rate of 9% for adverse effects in patients using homeopathic 
remedies in contrast to 6% in the placebo group. A meta–analysis (55) of 3,437 patients in 25 
placebo-controlled RCTs, reported 33 cases of adverse effects for patients treated with 
homeopathy and 97 for patients treated with placebo. Data from observational studies and 
surveys (38) reveal that reported adverse effects from homeopathic treatment fluctuates between 
2% (5) and 11% (56). Cases of adverse effects related to homeopathic practice have been reported 
in the literature (3, 57, 58), and a systematic review of case reports published in 2012 (64)(59) found 
that among the 38 primary reports included, 30 pertained to direct adverse effects of homeopathic 
remedies and another eight were related to adverse effects caused by substituting homeopathy for 
conventional medicine. 
In conclusion, direct risk in homeopathy is found to be low. However, remedies of low dilutions 
are connected with direct risk associated with the pharmacologically active remedy. In addition, 
these remedies may impose indirect risk that is linked to practice and the concept of homeopathic 
aggravation (figure 9-4). As previously discussed, remedies of high dilutions cannot have a 
pharmacological effect and a direct toxicological risk from these remedies is impossible. The risk 
related to the remedies of high dilutions is therefore indirect and related to homeopathic practice 
(see figure 9-4). With regard to homeopathic theory and potential risk to patient safety the 
concept of homeopathic aggravation may represent the greatest threat since it allows an increase 




Figure 9-4 Risk in homeopathy with regard to possible pharmacological effects. Direct risk is only possible 
for homeopathic remedies of low dilutions. However, remedies of low dilutions may also impose indirect 
risk due to homeopathic practice. Adverse effects related to remedies of high dilutions must be due to 
indirect risk factors. 
Homeopathic aggravation 
According to homeopathic philosophy, homeopathic aggravation is a “temporary worsening of 
existing symptoms following the administration of a correctly chosen homeopathic prescription”. 
In homeopathic theory, homeopathic aggravation is generally seen as a favorable response to 
treatment and is expected to be followed by an improvement (7, 48, 60). George Vithoulkas (a 
respected homeopathic practitioner and author in the homeopathic community) defined initial 
aggravation even as the optimal reaction to be expected from correct, constitutional remedy (61). 
Therefore, in homeopathic theory, a temporary deterioration of the patient’s health status as part 
of the therapeutic process is widely accepted. 
The literature available regarding the occurrence of homeopathic aggravation in clinical practice, 
remains unclear. Some authors estimate that 75% of all chronic cases demonstrate appreciable 
aggravation of their symptoms during homeopathic treatment (60, 62). Other authors report a lower 
frequency of 10-20% in clinical practice (55). In a systematic review of homeopathic aggravations, 
Grabia and Ernst found, that four included trials reported 40 cases of aggravation in the placebo 
groups and 63 cases in the homeopathy groups. The authors concluded that although the included 
RCTs mentioned the phenomenon of homeopathic aggravations, the evidence was not strong 
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enough to provide support for the existence of aggravations. In conclusion, even though the 
physiological and pathophysiological basis of homeopathic aggravation remains unclear, the 
described worsening of symptoms and deterioration of the patients’ health status during 
homeopathic intervention appears to be frequent and thus relevant with regard to patient safety. 
9.4.3 How to differentiate between adverse effects and homeopathic aggravations 
According to conventional medicine, the worsening of the patients’ symptoms as a consequence 
of treatment is understood as adverse effect. Consequently, homeopathic aggravation is a part of 
the category adverse effects in conventional medicine. However, according to homeopathic 
theory, homeopathic aggravation is an independent concept from adverse effect and worsening of 
the symptoms is accepted to a certain degree and monitored as a part of the healing process. The 
figure below illustrates the different concepts. 
 
Figure 9-5 Based on conventional medical theory, homeopathic aggravation is defined as adverse effect. 
However, according to homeopathic theory the concept is distinct from adverse effect. 
Since homeopathic aggravation, according to homeopathic theory, is tolerant towards worsening 
of the patients’ symptoms, it is important that the homeopaths increase their awareness of adverse 
effects. It is important with regard to patient safety, that homeopaths do not ignore signs of 
serious adverse effects and thus provoke a dangerous situation for the patients. Consequences of 
overlooking serious symptoms are demonstrated in the case presented previously in this 
dissertation (3) and in a systematic review recently published (59). 
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There are several reasons for the need of criteria, acceptable to homeopaths that distinguish 
between acceptable homeopathic aggravations and adverse effects that make conventional 
treatment mandatory. Firstly, and most relevant, it will enhance patient safety, and secondly, it 
will allow comparison of safety data across studies which have to date no uniform definition of 
adverse effect vs. homeopathic aggravation. According to Hahnemann (the founder of 
homeopathy) (63) homeopathic aggravation consists of the same symptoms as the natural disease, 
whereas Kent (respected author and homeopath), argues that the symptoms of aggravation may 
be new symptoms that are different from those initially presented by the patients (64). Therefore, 
there was a need for developing a clear definition of homeopathic aggravation as compared to 
adverse effect that could serve as a basis for this research plan (65, 66). 
9.5 Aims of the research plan 
Previous research suggests that there is low direct risk related to homeopathic remedies. 
However, homeopathic aggravation which is a concept unique to homeopathic practice, may 
impose indirect risk since it is tolerant towards a worsening of the patients’ symptoms. Therefore, 
the global aim of this research plan was to explore, and provide more knowledge about patient 
safety in homeopathy, with a specific focus on risk related to the concept of homeopathic 
aggravation. Furthermore, initiate the development of a reporting system for adverse effects in 
homeopathy in order to enhance patient safety. The table at the next page presents the 
overarching aims (the specific aims will be reported along every single study separately), 




Table 9-2 The aims, research questions and methodology applied in this research plan. 
Aims Research questions Methodology Publication 







• Status of problem reported 
in the scientific literature. 
• Initiate the development of 
a reporting system for 
adverse effect. 
• Systematic review and meta-
analysis. Application of the 
CTCAE grading system by the 
first author, grading of 
adverse effects and 
homeopathic aggravations. 
1 








• Definition of the concept of 
homeopathic aggravation. 
• Development of criteria, 
which discriminate the 
concept of homeopathic 
aggravations from adverse 
effects.  
• Assess patient safety.  
• Focus group interview 
among lay homeopaths. 
• Focus group interview 
among medical homeopaths. 
2, 3 






particular risk on 
the patient. 
• How common are adverse 
effects in homeopathic 
practice? 
• Severity of adverse effects 
in homeopathic practice 
according to the CTCAE 
grading system.  
• Application of criteria to 
discriminate between 
homeopathic aggravation 
and adverse effects. 
• Comparison of adverse 
effects and identified 
homeopathic aggravations 
with regard to the CTCAE 
criteria. 
• Survey among homeopaths. 
• Applying the ICPC-2 coding 
for classification of initial 
complaints reported by 
patients. 
• Identification of adverse 
effects. 
• Application of the CTCAE 
grading system by two MDs 
independently, grading of 
adverse effects. 
• Differentiating homeopathic 
aggravations from adverse 
effects by applying the 
newly developed criteria. 
The process was performed 
by two homeopaths 
independently.  
• Comparing the identified 
homeopathic aggravations 
with the remaining adverse 
effects with regard to their 






10 Methods and results for this research plan 
In this section each individual study will be presented separately, including the following 
paragraphs. 
1. Specific aims of the study 
2. Specific methodology applied in the study 
3. Abstract of the publication 
The rationale for this strategy was that each individual study has different, yet interdependent 
methodologies. 
10.1 General methodology applied in this research plan 
Mixed method research is a recognized study design where the researcher mixes or combines 
quantitative and qualitative research techniques, methods, approaches, concepts or language 
within one research plan (67, 68). It allows the researcher to select and match design components 
that offer the best prerequisite to answer the research questions, and the design is a complement 
to traditional qualitative and quantitative research (67, 68). Quantitative research is often used to 
measure outcome from an intervention and support to generalize results from a qualitative study. 
In this research plan, quantitative research was applied to estimate risk and to evaluate how 
frequent adverse effects was reported in homeopathic practice. Qualitative research can generate 
hypotheses for quantitative research and test the theoretical framework for a quantitative method 
(69). The qualitative approach can help the researcher to gain access to the view of participants and 
can address how an intervention is used in practice (68, 69). In the present research plan, qualitative 
research was applied to develop a definition of concepts and criteria unique for homeopathic 
practice based on the views of the homeopaths. Both research approaches can provide 
information about different aspects of a phenomenon, which was the intention for applying the 
research design in this research plan. 
10.2 Paper I: Adverse effects of homeopathy, what do we know? A systematic review 
and meta-analysis of Randomized Controlled trials 
10.2.1 Aims 
The specific aims were: 
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1. Systematically investigate how homeopathic aggravations and adverse effects are reported 
in randomized controlled trials. 
2. Classify adverse effects and homeopathic aggravations according to the Common 
Terminology Criteria for Adverse Events (CTCAE). 
3.  Perform a meta-analysis in order to evaluate the risk for patients using homeopathy 
(consultation and/or homeopathic remedies) compared to the controls. 
10.2.2 Method 
 Systematic review and meta-analysis 10.2.2.1
The purpose of a systematic review is to provide clinicians, nurses, therapists, healthcare 
managers, policy makers and consumers with quality information on the effectiveness, safety, 
meaningfulness, feasibility and appropriateness of a large number of healthcare interventions. 
This method is appropriate when the researcher wants to investigate safety issues related to 
homeopathy. 
A systematic review is considered to provide the highest level of evidence in regard to the 
effectiveness of the interventions for a specific condition (70). In order to answer a specific 
research question, a systematic review has the potential to collect all empirical evidence included 
in the eligibility criteria (71) and minimize bias to provide reliable findings. 
Meta-analysis is a statistical combination of results from two or more separate studies (71). The 
potential advantages of meta–analyses include increase in power, an improvement in precision, 
and the ability to answer questions not posed by individual studies. Meta-analyses have however, 
the potential to adversely mislead the results, particularly in cases of a) inaccurate consideration 
of inappropriate study designs, b) biases within the studies, c) variation across studies, and d) 
reporting biases. 
 Common Terminology Criteria for Adverse Events (CTCAE) 10.2.2.2
The CTCAE guidelines include a descriptive terminology which can be utilized for reporting 
adverse events (36). The general CTCAE guidelines cover grades 1-5 where 1 is mild, 2 moderate, 




10.2.3 Abstract paper I 
Background 
Despite unclear mechanisms of effect and safety, homeopathic remedies are in widespread us,. 
To enhance patient safety, it is, therefore, essential to investigate risk associated with this 
treatment modality, particularly since adverse effects after homeopathy have been reported. A 
particularly important concept, which is unique to homeopathy, is homeopathic aggravation that 
reflects a transient worsening of the patients’ symptoms, before an expected improvement occurs. 
Moreover, it is vital that a distinction between homeopathic aggravation and adverse effects is 
established. There is a lack of systematic information on how frequent adverse effects and 
homeopathic aggravations are registered in studies. Therefore, a systematic review and meta-
analysis were performed. 
Method/Findings 
Sixteen electronic databases were searched for Randomized Controlled Trials with data regarding 
adverse effect and/or homeopathic aggravations. The searches were limited from the year 1995 to 
January 2011. Forty-one RCTs, with a total of 3967 participants were included. A subtotal of 35 
studies was included in the additional meta-analysis. 
Results 
A total of 68% of the included trials reported 806 adverse effects after treatment, and 12% 
reported 108 homeopathic aggravations. Both were classified mainly as minor (grade 1) and 
moderate (grade 2) according to the Common Terminology Criteria for Adverse Events, apart 
from five cases of homeopathic aggravations that were classified as serious (grade 3). The meta-
analysis found that adverse effects were reported to a similar degree in the placebo/ active control 
groups than in the homeopathy groups. The methodological quality was high, according to a 
method recommended in the Cochrane handbook for RCTs, was high. 
Conclusion  
Adverse effects and homeopathic aggravations were mainly reported as mild to moderate 
according to the CTCAE grading system. However, some cases of serious adverse effects were 
reported, which highlights the need for criteria that distinguish adverse effects from homeopathic 
aggravations. These results suggest a similar risk for homeopathic treatment compared to placebo 
and active controls, such as conventional medicine. The inconsistent use of safety terminology in 
the included studies was problematic and may bias this result. 
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10.3 Paper II: Is it possible to Distinguish Homeopathic Aggravation from Adverse 
Effect? A Qualitative study 
 Paper III: The Red Flag! Risk assessment among medical homeopaths in 
Norway: A qualitative study 
The method and aims for these two individual studies were more and less similar. They will 
therefore be presented in the same section. The types of study participants, however, differed. In 
study II the participants were lay-homeopaths and in study III they were medical homeopaths. 
10.3.1 Aims 
The specific aim for study II was 
1. To explore and compose criteria that may differentiate adverse effects from homeopathic 
aggravations. 
The specific aims for study III were 
2. How do medical homeopaths understand and discriminate between homeopathic 
aggravations and adverse effects in clinical practice? 
3. How do medical homeopaths assess patient safety in their medical practice? 
10.3.2 Method 
 Focus group interviews 10.3.2.1
Qualitative methodology has been identified as fundamental to understand and describe the 
philosophical basis, key treatment components and contextual frameworks of CAM modalities 
(16, 72) in the field of CAM. This type of design is usually appropriate when existing theory or 
research literature on a phenomenon is limited (73). Focus group interview is a qualitative 
approach utilized to obtain in-depth knowledge and viewpoints from participants.  In focus group 
interviews the study participants can discuss issues within the context of their own shared cultural 
background (74). The group interaction can generate unique insights into shared experiences and 
social norms, and is appropriate when the goal is to understand differences in perspectives 
between groups of people, or to uncover factors that influence opinions or behavior. This can be 
productive especially with socially marginalized populations, and in discussing potentially 
sensitive topics (75, 76). Furthermore, they may contribute to a deeper understanding and thorough 
knowledge of important health issues, especially in situations with limited knowledge of the 
phenomenon of interest (77). This type of interview is a method of explicit inclusion, which uses 
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the group interaction to generate data (78). The communication between the participating 
homeopaths provided new insight into the concepts that are unique for homeopathy. The dialogue 
between participants, which can reveal diversity regarding the understanding of adverse effects 
and homeopathic aggravations, was the decisive factor for utilizing focus groups, rather than 
individual interviews for this. The study participants had thorough experience operating as 
homeopaths from clinical practice, where they evaluated adverse effects and homeopathic 
aggravations on a daily basis. They were therefore able to debate the research questions as 
experts based on long-lasting experience as homeopaths.  
 Homeopathic case analysis 10.3.2.2
Case analysis explains how homeopaths evaluate patients. In such an analysis the homeopaths 
evaluate the patients’ ability to recover, the extent of their illness and their plausible response to 
the treatment (7). The main goal is to determine the patients’ general condition and the 
development of the disease. The homeopath will for example monitor the state of the entire 
organism, expressed in homeopathic theory as “energy level”, “the mental-emotional state”, and 
the “key symptoms” of the patient (79). If correctly applied, case analysis provides a “close-
method” monitoring tool within homeopathic theory, which should allow identification of serious 
complications. 
10.3.3  Abstract paper II  
Background 
Homeopathic aggravation is a temporary worsening of existing symptoms following the 
administration of a correct homeopathic prescription. The aim of this study was to explore and 
compose criteria for the purpose of differentiating homeopathic aggravation from adverse effect. 
Material and Methods 
A qualitative approach was employed using focus group interviews. Two interviews including a 
total of eleven experienced homeopaths were performed in Oslo in Norway. The practitioners had 
practiced classical homeopathy over a period of 10-32 years. For the analysis of text data a 
qualitative content analysis was applied. The definition of codes was composed prior to as well as 
during the data analysis. 
Results 
Aggravations were found to be subtle and multifaceted events. Moreover, there is a need for 
highly skilled homeopaths to identify and report aggravations. The definition of adverse effect 
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may be “an undesirable effect of a remedy”. This is a pragmatic and flexible definition, more in 
line with the holistic paradigm represented by the homeopaths. In addition, eight criteria 
distinguishing aggravation from adverse effect were composed. Highly sensitive persons hold a 
unique position regarding safety. Identifying these patients is imperative, enabling correct 
treatment and avoidance of undesirable treatment effects. 
Conclusion 
This study comprised a rigorous exploration of the homeopaths’ views and experiences regarding 
aggravations and adverse effects. The eight criteria developed in this study may ensure patient 
safety and support therapists in their identification of “an undesirable effect of a remedy”. 
10.3.4  Abstract paper III 
Background 
Homeopathy is widely used, and many European physicians practice homeopathy in addition to 
conventional medicine. Adverse effects in homeopathy are not expected by homeopaths due to 
the negligible quantities of active substances in a remedy. However, the question was posed 
whether homeopathic aggravation, which is described as a temporary worsening of existing 
symptoms following a correct homeopathic remedy, should be regarded as adverse effects or 
ruled out as desirable events of the treatment. In order to improve knowledge in an unexplored 
area of patient safety, investigation was performed into how medical homeopaths discriminate 
between homeopathic aggravations and adverse effects, and how they assess patient safety in 
medical practice. 
Method 
A qualitative approach was employed using focus group interviews. Two interviews including a 
total of seven medical homeopaths were performed in Oslo in Norway. The participants practiced 
homeopathy as well as conventional medicine. A qualitative content analysis was applied to 
analyze the text data. The definition of codes was composed prior to as well as during the data 
analysis. 
Results 
According to the medical homeopaths, a feeling of well-being may be a criterion to distinguish 
homeopathic aggravations from adverse effects. There was disagreement among the participants 
regarding possible adverse effects as a result of homeopathic treatment. However, they agreed 
that when an incorrect remedy was administrated, it could create a disruption or suppressive 
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reaction in the patients. This was not perceived as adverse effects but a possibility to prescribe a 
new remedy on the emergence of new symptoms. This study revealed several advantages for the 
patients as the medical homeopaths looked for dangerous symptoms, which may enhance safety. 
Moreover, the patients were given time and space, enabling the practitioners to see the complete 
picture. A more comprehensive toolkit provided the medical homeopaths with a sense of 
professionalism. 
Conclusion 
This explorative qualitative study investigated the understanding and assessment of risk 
according to medical homeopaths based on their experiences from clinical practice. A feeling of 
well-being emerging shortly after having taken the remedy was the most important criterion for 
discriminating between homeopathic aggravations and adverse effects in clinical practice. The 
medical homeopaths applied the view of both professions and always looked for red flag 
situations in the consultation room. The combination of their knowledge from the two treatment 
systems may benefit the patients. These tentative results deserve further research efforts to 
improve the safety for patients using homeopathy. It is recommended that further research 
improve and develop concepts unique to homeopathy, thus, enabling validation and 
modernization of this medical practice. 
10.4 Paper IV: Risk in homeopathy: Classification of adverse effects and homeopathic 
aggravations – A cross Sectional study among Norwegian Homeopaths 
10.4.1 Aims 
The specific aims were 
1.  To describe what kind of reactions, reported by the patients, two weeks after taking 
homeopathic remedies and to classify these into no reactions, improvement of symptoms 
and worsening of symptoms. 
2. To grade the severity of the worsening of symptoms according to the Common 
Terminology Criteria for Adverse Events (CTCAE). 
3. To classify the worsening of symptoms into homeopathic aggravations or adverse effects. 
4. To describe the recommendations the homeopaths gave to their patients with regarding 




 A cross-sectional study 10.4.2.1
A cross-sectional study is often used to estimate the prevalence of a condition in a population and 
is often applied when calculating risk factors related to a disease (80). All information in a cross-
sectional study is collected at a set point in time and provides a snapshot of the current situation, 
known as ‘point prevalence’(81), which allows the researcher to obtain useful developmental data 
in a relatively short period of time. The design is intuitively easy to understand, and enables 
examination of many variables simultaneously (81). 
 International Classification of Primary Care (ICPC-2) 10.4.2.2
The initial complaints reported by the study participants were classified according to the 
International Classification of Primary Care – 2nd edition (ICPC) (82). The system includes three 
important elements: i) Reasons for encounter (RFE), ii) diagnoses or problems, and iii) process of 
care. RFE reflect the patient’s view. Process of care (decision, action, intervention or plans) 
reflects the care process, and the assessment (diagnosis or health issue) reflects the physician’s 
view (82). It was a conscious choice to apply this classification system in the present study, as the 
ICPC-2 is a standard classification system and used worldwide. A standardized and validated 
system facilitates the comparison across studies. 
10.4.3  Abstract paper IV 
Introduction 
Patient safety is central for all health care practices and registration of adverse effects is done to identify 
treatment that might pose a risk for patients. In homeopathy there is an ongoing discussion of how to 
classify a reaction to treatment as adverse effect (AE) or homeopathic aggravation (HA). Homeopathic 
aggravation is understood as a temporary worsening of existing symptoms following the administration of 
a homeopathic remedy, which is subsequently followed by an improvement. However, this concept may 
impose a particular risk, as it is tolerant towards a worsening of the patients’ symptoms. The aim of this 
study was therefore to explore classification of patient reported reactions as AE or HA. 
Methods 
In a cross sectional survey, patients were asked to register any reactions they had experienced 14 
days after an initial homeopathic consultation. Two Medical Doctors (MDs) evaluated all 
reported worsening of symptoms and graded these for severity according to the Common 
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Terminology Criteria for Adverse Events. Then two homeopaths evaluated and classified the 
symptoms as homeopathic aggravations according to whether it was i) increase of patient’s 
existing symptoms, ii) and/or a feeling of well-being that emerges 1-3 days after taking the 
remedy, iii) and/or headache and/or fatigue may accompany these symptoms. 
Results 
Among the 288 participants, 154 (53%) reported no reactions, 60 (21%) improvement and 74 
(26%) worsening of symptoms (adverse effects). The adverse effects was classified as CTCAE 
grade 1 (minor, 66%) or 2 (moderate, 34%), while none were graded as grade 3 (serious), 4 (life-
threatening), or 5 (lethal). A total of 49 (66%) participants experienced adverse effects that were 
classified as homeopathic aggravations (HA, 17% of all participants). Of these 73% (n=36) were 
classified as CTCAE grade 1 and 27% (n=13) as grade 2. For those that were classified as 
adverse effects (9% of all participants), 52% (n=13) was grade 1 and 48% (n=12) grade 2, giving 
a tendency towards milder severity for those classified as HA (p=0.065). 
Conclusion 
Patients reported a substantial part of the short-term reactions after taking homeopathic remedy 
(medication) as a worsening of symptoms. These reactions were classified only as mild or 
moderate adverse effects. There was a tendency for homeopathic aggravations to be classified as 
less severe. More studies are needed to confirm the existence of homeopathic aggravation and, 
accordingly, how to classify the concept in a clinical meaningful way. 
11 Discussion 
Findings from this research suggest that homeopathy is generally associated with low direct risk, 
which is in line with international studies. Moreover, direct risk is only possible for homeopathic 
remedies of low dilutions since they have possible pharmacological effects. However, remedies 
of low dilutions may also impose indirect risk due to homeopathic practice. Remedies of high 
dilutions cannot have a pharmacological effect and a direct toxicological risk from these remedies 




The concept of homeopathic aggravation imposes a particular risk, as it allows the health status 
of the patient to deteriorate before it improves. Therefore, the practitioner in clinical practice 
must decide whether the deteriorations of the patient’s symptoms are homeopathic aggravations 
or not. In the guidelines developed to distinguish homeopathic aggravation from adverse effect in 
this present research plan, it turned out that a feeling of well-being was the most important 
criterion (papers II and III). From a safety perspective, however, the time based criterion (1-3 
days) may ensure that patients are referred to conventional care in due time. Consequently, there 
will be a probable increase in the number of patients being referred to conventional care. A time-
based criterion allows differentiating the concept homeopathic aggravation from adverse effect 
within homeopathic theory, and thus has a good potential for acceptance among homeopaths. In 
addition, clear definitions and criteria are important and will moreover improve the internal 
validity of the study. 
It is furthermore important to compare data on homeopathic aggravations from multiple studies in 
a reporting system. A reporting system for adverse effects should provide the following 
information: 
1. Differentiate adverse effects from homeopathic aggravations 
 2. Patients included in research should have their symptom patterns rated at baseline before the 
intervention begins 
3 Adverse effects should be reported separately for treatment and control groups. 
4. If possible, the exact number of adverse effects should be reported in all subjects 
 5. A grading system, such as the CTCAE, should be used when reporting adverse effects and 
homeopathic aggravations. 
11.1 How frequent are adverse effects with regard to homeopathic treatment? 
According to the findings from this research plan, there is clear evidence for the appearance of 
adverse effect related to homeopathic treatment. When applying the definition of homeopathic 
aggravation, a total of 9% of the study participants reported adverse effects. The adverse effects 
were graded as CTCAE grades 1 or 2, understood as mild to moderate events (papers I and IV). 
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Results from other studies demonstrate that adverse effects related to the homeopathic remedy 
fluctuate between 2% (5) and 11% (56). However, the magnitude and seriousness of risk related to 
conventional medications are evidently higher. In a systematic review of the use of Aspirin 
(acetyl-salicylic acid), involving 9 studies and more than 1,000 participants, a 30% increase in the 
risk of serious bleeding was demonstrated (83). 
Remedies of low dilution that are made from mother tinctures are principally able to be 
pharmacologically active. These remedies may be administered in concentrated forms (D6 or 
D12) and have a risk profile similar to that of herbal medicine (6). Some homeopathic remedies 
are produced from sources constituting potential risk hazards (6), such as remedies that are made 
from animal and human sources, which may contain pathogenic agents that represent a risk of 
contamination. Hence, satisfactory manufacture practice is imperative to avoid safety hazards. 
Almost half of the lay homeopaths included in this research plan (65), claimed that homeopathic 
treatment in general does not cause any adverse effects, which clearly does not represent 
published research or clinical practice (54, 59). Therefore, it is important to increase the awareness 
of potential adverse effects among homeopathic practitioners. In order to enhance safety, the 
homeopaths should make sure that their patients receive a conventional diagnosis for their 
complaints or diseases if the worsening of symptoms lasts for more than three days. However, 
this is not applicable for all complaints for example high fever in children. The case study 
presented in the introduction (3) demonstrates how serious the consequences of homeopathic 
treatment can be. Furthermore, it highlights the need for an appropriate and relevant training for 
homeopaths, and a reporting system for adverse effects. Moreover, it reveals the need for criteria 
that enable homeopaths to distinguish between adverse effects and homeopathic aggravations, 
and which gives a clear signal, when the condition of the patient is beyond their skills. 
In conventional medicine, adverse effects of the treatment are accepted to a certain degree. The 
reason is that the beneficial effects of the treatment will compensate for them. For example, in 
cancer treatment, chemotherapy is related to severe adverse effects, such as nausea, fatigue and 
heart failure. This is accepted since the beneficial effects of the treatment are to shrink the tumor 
and, thereby, fight the cancer. Hence, the advantages exceed the disadvantages. This is especially 
true for patients with severe diagnoses, who are more willingly to endure severe adverse effects, 
as long as they are eventually healed. For patients with less severe diagnoses, adverse effects are 
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unacceptable. However, in homeopathy, patients with for example atopic eczema are willing to 
endure deteriorations they otherwise would have rejected, because they anticipate a subsequent 
improvement. Consequently, this implies risk for the patient, and it is imperative that the 
homeopaths evaluate the symptoms properly, and refer the patient to conventional care when 
necessary. 
Findings from this research demonstrated frequent incidences of adverse effects in homeopathic 
practice, including those interpreted as homeopathic aggravations. It was found that two out of 
three adverse effects reported by patients after taking a homeopathic remedy can be classified as 
homeopathic aggravation. More importantly, there was no difference in severity between 
homeopathic aggravations and adverse effects, suggesting similar risk profiles between the two 
concepts. Even though there was a trend for homeopathic aggravation to be classified less severe. 
Compared to other studies, the frequency of homeopathic aggravations was found to be higher 
(17%) in the studies presented here. In other studies the frequency of homeopathic aggravations 
fluctuated between 6% (64) and 8% (5). 
 Homeopathic aggravation may induce a particular risk to patients in homeopathy, because the 
patients may suffer from deteriorations in their health status. This may further complicate the 
patients’ treatment, or excessively delay the consultation with their GP. It is therefore important 
that the homeopaths in clinical practice, closely observe and monitor the patients’ symptoms in 
order to decide the direction of the therapeutic process, for instance towards a further 
deterioration or improvement of the symptoms (7, 79). Results from the present research suggest 
that homeopaths applied homeopathic case analyses when evaluating the patients’ symptoms in 
order to avoid hazardous situations (7). However, if the homeopaths do not possess the knowledge 
required the concept of homeopathic aggravation may impose risk for the patients. Moreover, it is 
important to determine the patients’ symptoms as homeopathic aggravations or adverse effects. 
Findings from this research suggest that both lay as well as medical homeopaths are able to make 
this distinction accordingly (65, 66). Moreover, the patients would benefit from improved 
cooperation between lay homeopaths and medical doctors, because this desirable situation will 
enhance patient safety. Furthermore, patients highly valued input from their medical doctors 
about the use of CAM (84). A study by Breitsameter (85) however, identified ethical problems 
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regarding the physicians’ inability to provide information about the combination of CAM, 
including homeopathy, and conventional care. 
A pragmatic and descriptive definition of homeopathic aggravation was utilized in this study, 
without suggesting any physiological and pathophysiological mechanisms for the concept. The 
operative definition allowed the identification of situations within homeopathic theory, where 
conventional care is unequivocally needed. This approach will increase patient safety within 
homeopathic practice. 
11.2 Is homeopathy generally safe? 
In conclusion, homeopathic treatment is generally associated with low direct risk (5, 38, 54, 86) and 
the data from the research presented here confirm these results. The risk profile of the 
homeopathic remedies is minor, however, there is a potential for indirect risk related to 
homeopathic practice (see figure 11-1). In that respect it is imperative to distinguish homeopathic 
aggravations from adverse effects as homeopathic aggravation may impose a particular risk on 
patients. The criteria developed may assist homeopaths in distinguishing between homeopathic 
aggravation and adverse effects. Furthermore, the results show that adverse effects and 
homeopathic aggravations are common in clinical practice. However, the events were classified 
as mild to moderate with no difference between homeopathic aggravations and adverse effect 




Figure 11-1 Pharmacological model in association with indirect risk in homeopathy. Indirect risk is related 
to clinical practice, the practitioner and applies likewise to remedies of low and high dilutions. In clinical 
practice the practitioner must decide whether the deteriorations of the patient’s symptoms are 
homeopathic aggravations or not. The developed criteria to distinguish between homeopathic 
aggravations and adverse effects will provide a tool within homeopathic theory to facilitate this process. 
11.3 The concept of homeopathic aggravation: Potential explanations unrelated to 
homeopathic theory and a general risk evaluation   
11.3.1 Nocebo effect 
Homeopathic remedies may impose risk known as the nocebo effect (21). Nocebo effects are 
defined as the development of negative effects that are attributed to a medication, albeit the drug 
itself does not cause the provocation of these symptoms (21, 87). The development of adverse 
effects after placebo intake has been reported for medical conditions such as depression (88) and 
cancer (89). Nocebo effects are estimated to account for 72% of drop-outs in drug groups of 
fibromyalgia trials (90). Observations from clinical trials indicate that patients’ expectations play 
an important role in the development of nocebo effects. If patients were informed about potential 
adverse effects of a specific drug, they reported more symptoms than patients who were given 
limited information about potential adverse effects (91). Moreover, it seems that conditioning 
(Pavlov’s dogs) and associative learning may activate the development of nocebo effects, 
although there is weaker evidence for their involvement in nocebo effects compared to their role 
in developing placebo responses. A frequently cited clinical example for the conditioning of 
adverse effects is the development of anticipation nausea in patients undergoing chemotherapy 
(21). 
Data from this research (paper IV) demonstrated that patients rather often experienced 
homeopathic aggravations during treatment. An explanation for such a high frequency may be 
that many homeopaths inform their patients that homeopathic aggravations might occur during 
treatment. Health care providers should be aware that all interactions with the patients have the 
potential to result in expectations. Consequently, information that patients receive prior to 
treatment is of particular relevance (21). 
11.3.2 Natural history of disease 
The natural history of a disease is a theory about the diseases’ normal course in the absence of an 
intervention. The central question for studies of prevention and treatments (clinical trials) is 
whether the use of a particular preventive or treatment measure can change the natural history of 
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the disease in a favorable direction, by reducing or preventing clinical manifestations, 
complications or death (41). The natural history of disease refers to a description of the 
uninterrupted progression of a disease in an individual from the moment of exposure to causal 
agents until recovery (figure 10-2). Knowledge of the natural history of disease is important for 
disease prevention and control. Moreover, the natural history of disease is one of the major 
elements of descriptive epidemiology (41) (see figure 10-2). Modification of the model has been 
made for study purposes. 
If a patient visiting a homeopath experiences worsening of the symptoms, the homeopath must 
evaluate the situation. If the patient sees the homeopath during a point in time, when the 
symptoms are close to peak, he or she will experience an initial worsening of symptoms, 
followed by an improvement. Therefore, homeopathic aggravations may be understood as the 
“natural history of disease” as the patients will experience a worsening of the symptoms, even if 
they simultaneously experience a feeling of well-being (improved sleep). This is visualized in 
figure 11-2 through the escalating curve. If the worsening of these symptoms lasts for more than 
three days, and the patients feel worse, and there are no signs of well-being, it must be regarded 
as adverse effects, or the disease is more severe than anticipated (please see section 11.3.3 “The 
iceberg model”, also see fig 11-4). Consequently, the curve will peak at a much later stage. In 
these cases the homeopaths have to refer the patients to conventional care. 
 
Figure 11-2 The natural history of disease. 
Reference source: Centers for Disease Control and Prevention. Principles of epidemiology, 2nd ed. Atlanta: U.S. 
Department of Health and Human Services; 1992. 
It can be assumed that a pathological condition, such as a knee pain, will peak at some point and 
then eventually subside as long as it does not follow a chronic course. An ineffective treatment 
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will not influence the natural course of the disease, whereas an effective treatment will lower the 
peak and most likely flatten the slope of the curve, so that the symptoms are either less intense 
and/or will subside earlier. This scenario is visualized in figure 11-3. 
 
Figure 11-3 Improvement of symptoms which flattens the curve following an intervention. 
Reference source: Hoffman GA, Harrington A, Fields HL. Pain and Placebo: What we have learned. Perspectives in 
Biology and Medicine.2005; 48(2): 1708-12. 
Research related to placebo suggests that patients will seek treatment when the symptoms are at 
their most intense, meaning near the peak of the curve. Hoffmann et al (92) postulate that as the 
patient’s initial symptoms are at the worst when visiting a practitioner, the patient will most 
likely experience a decrease in the symptom level at the second visit to the practitioner. The 
decreased symptoms may be attributed to the treatment, placebo, to the natural history of the 
disease (41, 93).  
If a patient with common cold symptoms suddenly deteriorates during the night, with a 
temperature increase beyond 40 degrees, and develops a rash that does not disappear when a 
drinking glass is pressed to the skin, and complains about pain in the neck, the situation is 
serious. This patient must be sent to the hospital immediately, as the possible presence of 




Figure 11-4 Acceleration of symptoms in an acute situation.  
When assessing the symptoms of the patients, the homeopaths may apply the model as described 
in papers II and III. If the symptoms are severe, last for more than three days and there are no 
therapeutic signs, such as a feeling of well-being, the symptoms must be regarded as a severe 
adverse effect or a representation of much more severe and different diagnoses with an initially 
similar symptom pattern. 
11.3.3 The iceberg model 
Hemingway had a style of writing he referred to as the iceberg theory in which written words in a 
story focus on surface facts, those easily seen. However, beneath and behind the words is a more 
complete structure supporting the story. In the theory of diseases, the iceberg model is a metaphor 
emphasizing that for virtually every health problem, the number of known cases of disease is 
outweighed by those that remain undiscovered (94), much as the unseen part of an iceberg is much 
larger than the part that is visible above the water (95). In order to fit the purpose of the present 
research, the iceberg model has been modified and connected to the theory about the natural 
course of disease. In this way the model can be applied to individual health issues (see figure 11-
5). 
Catching a cold is normally an event that occurs once or twice during the winter season and many 
patients seek the help from a homeopath, especially if this is a recurring event. If the symptoms 
of a cold persist and the patient develops fatigue and weakness, the homeopath should be 
concerned and closely follow the patient on a daily basis. These symptoms are unacceptable and 
the patient should be referred to conventional care if no signs of improvement appear. If it turns 
out that the patient is then diagnosed with pneumonia, the cold was “the top of an iceberg”. The 
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cold represented superficial symptoms, while a far more serious disease that was developing 
underneath (figure 11-5). In order to ensure patient safety in such cases, it is important that the 
homeopath follows the patient carefully by assessing the symptoms frequently, and refers the 
patient to conventional care, if no therapeutic improvements appear. 
Another, even more serious example is a patient with cough, shortness of breath and breast pain 
who visits a homeopath and is later diagnosed with lung carcinoma. Therefore, the iceberg model 
suggests that an awareness of potentially serious differential diagnoses is mandatory for a 
practicing homeopath, so the patient is transferred immediately to conventional care, if the first 
sign of a “red flag” situation occur. An awareness and alertness for red flag situations should 
always be present when observing and monitoring patients’ symptoms. 
 
Figure 11-5 The iceberg model emphasizes that minor complaints or symptoms are common, but they 
may represent more severe different diagnoses. 
11.4 Methodological aspects 
11.4.1 Focus group interview 
In this research plan a qualitative content analysis was applied to analyze the transcribed 
interviews. A content analysis is a systematic examination of text by identifying and grouping 
themes, classifying and developing categories and performing the coding (78). The analysis is a 
flexible method of analyzing text data (73). 
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Content analyses are usually applied when theory or prior research exist, but the research or 
theory are incomplete or would benefit from further investigation (73). This was the rationale for 
applying the analysis in the present research plan. Moreover, the success of content analyses 
depends on the coding process. In the two qualitative studies presented here, the codes were 
defined both prior to and during the data analysis. Hence, we used elements from conventional 
and direct content analyses (mixed type). The basic coding process was organized in large 
quantities of text, which was further adapted into fewer categories (96). Codes defined prior to the 
interviews were related to the main topics of the studies, such as homeopathic aggravations and 
adverse effects. The codes the benefit of using both homeopathy and conventional medicine 
(article III) and highly sensitive patients (article II) emerged from the data material. This coding 
enabled emergence of new aspects of the themes in question. 
The coding and categories were also organized according to homeopathic case analyses (7). Case 
analyses explain how homeopaths evaluate their patients and explore the various steps in the 
treatment process. The homeopaths assess patient’s symptoms, the patient’s ability to heal, and 
how they respond to the treatment in this process. The application of this approach enhanced the 
reliability of the present study as it anchors the coding and categories to clinical practice. 
The candidate has worked in clinical practice as a homeopath for nearly 30 years. This 
background was an advantage when selecting homeopaths for this study, as the candidate knew 
that highly skilled homeopaths were needed to get solid information about homeopathic 
aggravations. It takes several years of clinical practice to become experienced in evaluating the 
patients’ symptoms and, thus, being able to add new aspects to the field. This selection criterion 
may, however, have biased the findings in this study, as the selected informants might have 
represented background and experience akin to those of the candidates, while other categories of 
homeopaths were excluded. We believe, however, that the selection of skilled and experienced 
homeopaths has provided reflections firmly rooted in the Norwegian homeopathic tradition. 
The two co-authors of the qualitative papers are not homeopaths, nor do they have in-depth 
knowledge of homeopathic theory. However, one of them is a social scientist with previous 
research experience in risk communication and risk perception among CAM patients (97, 98), and 
the other has experience from clinical practice and research regarding adverse effects in 
acupuncture (99). Both of them have experience with qualitative research and have contributed to 
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reflections of the codes in the analyzing process. This can be viewed as a triangulation of the 
results. Such an analytic approach enhances the reliability of the study. 
To reduce bias and improve validity of the study, the co-authors participated in the interviews, 
approved and elaborated the interview guide (developed and) used in the interviews (the 
interview guides are available at the end of the document, appendices 1 and 2). Further, they read 
and discussed the data derived from the interviews several times to enable coding and 
development of categories and themes (69). Such an analytical approach enhances the reliability of 
the study. Based on the content analysis, a model of how to distinguish homeopathic aggravations 
from adverse effects was developed in study II and refined in study III. 
To enhance validity and theoretical transparency, the themes and models were sent to the 
participants for comments and verification. One homeopath strongly disagreed with the model 
that distinguishes homeopathic aggravation from adverse effect, as he believed that homeopathic 
treatment did not cause any adverse effects. The majority, however, found the model relevant for 
clinical practice. This approach enhanced the generalizability of the two studies included in this 
research plan (69, 100). However, including less experienced homeopaths in the focus group 
interviews may have revealed other aspects and approaches about the phenomenon in question 
than the more experienced homeopaths provided. 
11.4.2 Cross sectional study 
Aslak Steinsbekk developed the first version of the questionnaire, used in the cross-sectional 
survey. He used the form for “reporting adverse effects” developed by Statens legemiddelverk (42) 
as a guide when designing the questionnaire. A small pilot study was performed, and 25 patients 
who had visited homeopaths received and returned the questionnaire to Steinsbekk. The aim of 
the pilot study was to measure face, content, criterion and construct validity (see the validity 
section). The questionnaires were delivered to the author of the present research plan, and some 
revision of the original questionnaire was made. Demographic data, such as occupation, level of 
education and marital status was added in the questionnaire and the number of reactions reported 
after treatment was reduced from five to two. 
Interpretation of the findings in cross-sectional studies requires considerable caution, as design 
allows no conclusions about causal relationships. In study IV the patients reported the reactions 
after the homeopathic treatment. However, the reasons for the reactions reported remain 
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unknown. The reactions could be related to the homeopathic remedy, the consultation or other 
factors, yet unknown. Moreover, as the design merely provides a snapshot of the situation, it is 
unsuitable for short-term conditions. This situation is called length-bias sampling. Length-biased 
sampling, refers to the fact that cases of long-duration illnesses will be over-represented and 
cases of short-duration will be under-represented in such surveys (81). 
The first step in designing a questionnaire is to have a clear purpose of the study. The topic and 
the type of information needed must be explicit to keep the questionnaire focused. The questions 
must measure according to the intentions (face validity), and the wording must be easy to 
understand and comparable with other studies. The length of the questionnaire must be sufficient 
to collect the information needed, and short enough to keep the informant focused when filling in 
the questionnaire (101). Moreover, the wording of the questions and the options available for 
answering, have a great influence on how people answer the questions. 
Almost all questions in a survey could be subject to criticism. However, open versus close 
questions and the “don’t know” response are the methodological issues discussed in the 
following. An open-ended question was used when asking for reactions in the questionnaire. 
(Question 1a: What was your experience/What was the reaction?) Open-ended questions allow 
the respondent to answer the questions in her own words. Such information may be more 
complete and accurate than information obtained through a more restricted format. It also avoids 
suggesting or imposing answers the informants may not have considered. Moreover, the open 
form allows future researchers to create new questions in a retrospective manner on the same 
subject (102). On the other hand, if the informant does not understand the questions, the answers 
may not provide the information needed (101). Another drawback is the difficulty of summarizing 
data, as the researchers must decide how to classify different answers. This may increase the risk 
of misclassification (80, 101). However, a combination of open-ended and close questions was used 
in the questionnaire: open-ended for the reactions and structured for the details. 
An additional issue to address is the possibility of offering a “don’t know” alternative. Before 
including this alternative, it is important to consider whether the respondent can actually identify 
with one of the options given or not (102). Where the respondent has an option, the “don’t know” 
option should preferably be left out to ensure that the respondent tries to answer according to 
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what is useful for the study. In the questionnaire used in this survey the “don’t know” option was 
used twice. 
11.4.3 Systematic review 
According to the protocol for this research plan, the first task was to perform a systematic review. 
The candidate spent the first six months performing database searches and methodologically 
assessing the studies included. The original plan was to include only RCTs. However, a previous 
researcher at NAFKAM suggested an additional inclusion of observational studies. This was 
done, and after one year the manuscript was submitted to PLoS ONE (peer-reviewed scientific 
journal) for publication consideration. The editor of PLoS ONE suggested extension of the 
searches from 1995-2011 (previous searches were from 2000-2011) and inclusion of German 
databases. Collaboration with two German researchers was established. To improve the quality of 
the study, it was decided to perform a meta-analysis of the adverse effects reported in the 
included studies. One of the German researchers is a statistician who had an appropriate software 
application to calculate odds ratio and fabricate the results in Forest Plots. The manuscript was 
revised accordingly. The study became huge, including 82 studies. After another year of 
reviewing with PLoS ONE, the journal rejected the manuscript. In May 2013, the manuscript was 
submitted to BMC Complementary and Alternative Medicine. The BMC reviewers suggested 
including only RCTs to make the study (and article) more transparent and accessible. This advice 
was also in accordance with that of the commission for this PhD thesis. Article I in this PhD 
thesis is now a systematic review of RCTs, including 41 studies. 
A systematic review must have a clear objective with defined eligibility criteria. A systematic 
search attempting to identify all studies that would meet the eligibility criteria was applied using 
the PICO format (see the Cochrane search string in figure 12-1). The first author performed the 
main searches, and the second author carried out the main German searches. The first and second 
authors assessed the studies, with assistance from the last author in cases of doubt. To assess the 
validity of the studies included a risk of bias table was generated. For the RCTs the risk of bias 
tables included the following criteria: Method (allocation sequence, method of concealment, 
blinding, loss to follow up), Participants, Intervention, Main findings, Power calculation, 
Intention to treat analysis and funding. When important information was missing in the studies, 




11.4.4 Internal validity 
Validity is an estimate of the accuracy of an instrument or study results. There are two distinct 
types of validity (70). One is internal validity that is the extent to which the study methods are 
consistent. The other is external validity that is the extent to which the study results can be 
applied to a larger population (70). In papers II and III in this research plan, the lay and medical 
homeopaths applied the same criteria when differentiating homeopathic aggravations from 
adverse effects, which enhances validity. 
There are four main types of internal validity that can be measured and discussed (103). The first 
concept is face validity, that is the extent to which a method measures according to the intentions 
(70). A survey is an appropriate method when the main research question is to investigate the 
prevalence of reactions after treatment in a population (104). The responders in this survey 
answered in a meaningful way, so the questions used in the questionnaire were relevant for the 
purpose of the study. This factor enhances the face validity of the survey used in this research 
plan. 
The second concept is content validity, that is the extent to which the questionnaire items cover 
the research area of interest (70). The questionnaire was designed to capture reactions after 
homeopathy, and the responders returned relevant answers. However, the questionnaire was 
designed without a clear question about homeopathic aggravation. An additional question about 
the concept of homeopathic aggravation, as it was operationalized in this study, would have been 
helpful to develop criteria to distinguish homeopathic aggravation from adverse effect more 
precisely (see the discussion in article four). 
The third concept is criterion validity that expresses an agreement with a gold standard (70) . There 
is a lack of available, validated questionnaires regarding registration of adverse effects in 
homeopathy. However, The Norwegian Medicines Agency has a notification form where patients 
and health care personnel can register adverse effects. This form was used as a model when 
designing the questionnaire used in this research plan. In addition, homeopath related questions 
were added to capture conditions specific to homeopathy. Question 5 in the questionnaire is an 
example: Did the reaction cause more symptoms than what you consider to be normal? This 




The fourth concept is construct validity that expresses an agreement with other tests available (70). 
Thus, the concept is understood as agreements with other tests in the field. Only three other 
studies have investigated the prevalence of homeopathic aggravations and adverse effects in 
patients using homeopathy. Moreover, only one study used a questionnaire that is published (56). 
However, due to an inconsistent use of terminology and standardized grading system for both 
adverse effects and homeopathic aggravations in previous research, it was necessary to establish 
common terminology for the terms used. To make the results comparable to studies from 
conventional care, a conventionally established grading system was chosen, which has not been 
used in previous research on homeopathic aggravations. 
11.4.5  Selection bias  
The best way to avoid selection bias in a survey is to invite the entire background population to 
participate in the study, which was done with the homeopath population as presented in paper IV. 
It is, however, reason to believe that the participating homeopaths had a positive attitude towards 
research in general, and this study in particular. This implies that homeopaths with negative 
research attitudes in general, or negative attitudes towards this research in particular, did not want 
to participate in the study. In that respect selection bias may have occurred in this research plan, 
as 64% of the invited homeopaths did not participate. 
A random sample is an alternative to ensure that the population studied reflects the background 
population (101). A common source of selection bias is self-selection. Self-referral of subjects is 
ordinarily considered a threat to validity because the reasons for self-referral may be associated 
with the outcome of the study. Even though the inclusion of patients was not self-referred, it is 
reason to believe that the participants were in favor of homeopathy and wanted to present the 
treatment as gentle as possible. This may have resulted in an under-estimate of adverse effects or 
an over-estimate of no reactions or improvement of symptoms. According to the homeopaths, 
who recruited patients to the survey, some patients did not want to participate in the study. They 
feared that the findings could result in negative publicity in the media and, thereby, harm 
homeopathy. It is, therefore, possible that there was a self-selecting bias among the patients. In 




11.4.6 Information bias  
When the groups in a population have been identified, personal information must be collected 
and used in the analysis. Information bias can be caused by measurement errors in the 
information needed and may cause bias in estimating an effect or exposure (70). Information bias 
may occur when the recall time is long (recall bias). It is unlikely that this occurred in study IV, 
as the participants were asked to report reactions 14 days after the homeopathic consultation. In 
addition, the participants received the questionnaire at the homeopath office in conjunction with 
the consultation. Thus, the participants had an increased awareness about reactions after the 
treatment. 
Another possible source of information bias may occur when a participant changes attitude due to 
inclusion in a research program (101). This change can be grouped into the three categories the 
cooperative attitude, the defensive or apprehensive attitude, and the negative attitude. The 
cooperative attitude is characterized as a strong desire to please the researcher, to perform well 
and with a desire to be positively evaluated by others. Users of homeopathy are likely to have 
positive attitudes towards homeopathy and be loyal to their homeopaths. This may influence the 
participants’ response by not reporting negative experiences with the homeopathic treatment. 
11.4.7 The response rate 
Low response rates are a challenge to the validity of the findings in a study. In paper IV the 
response rate was 41%, which may be a threat to the generalizability of the findings, because the 
non-responders may differ in significant ways from those who responded (101), and is a threat to 
the generalizability of the findings (103). However, the results regarding the prevalence of adverse 
effects and homeopathic aggravations in the present study, are in line with other studies (5, 56, 64), 
which suggests that nonresponse bias probably imposes no major threat to the validity of the 
results (103). Two thirds of the homeopaths invited to participate in the cross-sectional study, had 
several explanations for not wanting to participate in the present survey. When contacted on the 
phone, they explained that they had limited access to patients, or that participating was time 
constraining in a busy daily practice. Others explained that they did not have faith in the project, 
Many homeopaths find it difficult to accept that homeopathy can cause adverse effects. It seems 
like this subject is connected with some kind of taboo. However, new information and research 
about the topic may enforce a change in attitudes, and over time increase the homeopaths’ 
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awareness of possible adverse effects. Such attitude changes have been seen among 
acupuncturists. Due to unpopular findings, one researcher who investigated possible adverse 
effects of acupuncture treatment in Norway was excluded from the acupuncture association. 
Today, more than ten years later, acupuncturists deal with adverse effect of this treatment in a 
professional way. 
11.4.8 Reliability 
Reliability is the ability of a measure to produce equivalent or highly similar results on repeated 
administrations (101). The reliability of a questionnaire relates to the consistency of the responses 
across retesting, using equivalent instruments. Repeated testing is the oldest and most conceptual 
way to establish the reliability of a questionnaire (101). Test-retest was not applied in this survey. 
Recruiting homeopaths to participate in this survey was challenging for previously explained 
reasons. In addition, they found it time-consuming to distribute the questionnaires to their 
patients, which was the reason for not applying the test-retest approach in the present study. 
11.4.9  External validity and generalizability 
To enhance external validity, the definitions were sent to the study participants prior to the focus 
group interviews. All of them agreed on the definitions and the homeopath specific theories 
applied in this research plan. In addition, the candidate visited a homeopath library in Oslo to 
gather as much information and knowledge about homeopath specific theories as possible. A 
comprehensive database search regarding homeopathic aggravation was performed. This search 
resulted in nine scientific articles about homeopathic aggravations. These articles were used as a 
fundament to support and validate this research. 
In addition, an expert panel (homeopaths) assessed the external validity. This validity reflects the 
extent to which the homeopaths recognize this research as being relevant to homeopathic 
practice. A result of this research is two published papers that have been well received in the 
homeopathic community. Moreover, the feedback from the homeopaths, who the candidate met 
at international conferences, confirms that this research is both important and pioneering. 
Generalizability expresses whether the results found in one population can be true for other 
populations (70). The main question is whether the findings from this research plan reflect the 
homeopathic tradition in other countries. Investigating adverse effects and homeopathic 
aggravations among users of homeopathy has not previously been done in Norway. However, 
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findings from international studies are in line with the results from the present study (56, 64). The 
findings from the systematic review conducted in this research plan is in accordance with other 
studies (54). Only time will show if the criteria to distinguish homeopathic aggravations from 
adverse effects will be useful for homeopaths in clinical practice. More research into 
homeopathic practice may reveal other criteria, and adjust them to practice. 
11.5  Perspective for future research and practice 
The homeopathic community (54) requested more patient safety research in homeopathy, which 
ultimately would lead to a safety reporting system for adverse effects (105). Data from the research 
plan presented here suggest guidelines for researchers, applicable when reporting adverse effects 
of homeopathic treatment. These guidelines are merely an initial step towards improved risk 
assessment in homeopathy. However, further research is recommended for elaboration and 
validation purposes. These guidelines are imperative for the comparison of safety data across 
studies and for patient safety enhancement. 
Research suggests an underreporting of adverse effects in homeopathy. One method of 
encouraging patients to report adverse effects after treatment would be to establish a web-based 
system. This could be achieved if NHL applies a user–friendly tool on their web page. This step 
may increase the attention of adverse effects and enhance patient safety. 
According to data from this research, several homeopaths believe that homeopathy is free of risk 
and does not cause adverse effects. This attitude among homeopaths underlines the need for 
improved awareness of adverse effects and red flag situations in clinical practice. It is, therefore, 
important that the homeopaths inform their patients to stay in contact if the worsening of 
symptoms last for more than three days. 
 Thus, it is imperative that homeopath training increase their attention on the subject and teach 
the students about red flag situations and possible adverse effects of the treatment. The criteria 
developed to distinguish between homeopathic aggravations, which may or may not represent the 
natural course of the disease, and adverse effects will provide a tool within homeopathic theory to 
facilitate this process. 
The current legal regulation for CAM practitioners, including homeopaths, in Norway states that 
everyone can practice CAM as long as they do no harm. However, findings from this research 
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plan suggest that it is imperative that the practitioners have both medical and homeopathic skills 
to safeguard this treatment modality. Consequently, The Alternative Medicine Act (Lov om 
alternative behandling) should be altered and mandatory requirements about medical and specific 
skills among CAM practitioners (including homeopaths) should be implemented. 
12 Supplementary data 
An example of a search string for the systematic review is attached below (figure 12-1). The 
search strategy, using the Boolean operators OR/AND is presented. MeSH and truncation 
symbols were utilized where available. Titles, abstracts and keywords were searched. 
 




Table 12-1 Risk of bias table for the RCTs. 
Study Zabolotnyi (2007) Efficacy of a Complex Homeopathic Medication (Sinfrontal) 
in Patients with Acute Maxillary Sinusitis: A Prospective, Randomized, 
Double-Blind, Placebo-Controlled, Multicenter Clinical Trial 
Methods Complex homeopathic medication (Sinfrontal) versus placebo in patients with acute 
maxillary sinusitis. 
Allocation sequence: A balanced 1:1 randomization using a block size of four to 
randomize the patients into the groups, according to a predefined computer-
generated list. The block size was unknown to the trial personnel/investigator. 
Method of concealment: Each investigation site was randomized using two 
consecutive blocks. 
Blinding: Patients, investigators and the data monitoring committee were blinded to 
the treatment allocation.  
Loss to follow up: One subject in the homeopathy group and six in the placebo 
group.  
Participants Inclusion criteria: Males and females between the ages of 18-60 with confirmed 
radiographic diagnosis of acute maxillary sinusitis for the last eight days or longer. 
Exclusion criteria: Patients with obstructive anatomic lesions in the nose, previous 
nose surgery, recurrent sinusitis, allergic rhinitis, other lung and upper respiratory 
diseases, bronchitis, treatment with antibiotics and other medications for sinusitis, 
hypersensitivity to the investigated drug, cardiovascular diseases or unstable 
diabetes mellitus, hepatic dysfunction, any alarm symptoms, heavy smoking, 
pregnancy or breastfeeding women. 
Intervention 113 subjects were randomized to receive either Sinfrontal (Cinnabaris D4, Ferrum 
D3 and Mercurius solubilis D6) (n=57) or placebo (n=56) which was matched to 
the active medication regarding colour, smell, taste and viscosity. Subjects in both 
groups were to take one tablet every hour until the first improvement, followed by 
two tablets three times a day for 22 days. Additional medication was Paracetamol 
500mg for fever (allowed for seven days) and Saline inhalations, if necessary. At 
the end of the double blind phase, each subject was asked to enter into a prospective 
eight-week post-treatment observational phase (n=105). 
Main findings The results of this trial appear to demonstrate that Sinfrontal is significantly better 
than placebo as an effective treatment for acute maxillary sinusitis, both bacterially 
and virally infected sinusitis confirmed by radiography. 
Notes Power calculation: Performed. 
Intention to treat analyses: Performed.  




Number of adverse 
effects  
Homeopathy group: 8 cases of gastro-intestinal disorder. Six cases were due to 
lactose intolerance. Five were classified as mild and three as moderate.         




Verbatim description Not reported. 
Homeopathic remedy 
that produced adverse 
effects or aggravations 
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Ved NAFKAM (Nasjonalt forskningssenter innen alternativ og komplementær medisin), er vi 
i gang med et forskningsprosjekt om homeopati og bivirkninger. Vi vil blant annet
gjennomføre en spørreundersøkelse blant 1500 pasienter som oppsøker homeopat for første 
gang, å spørre dem om deres erfaringer og opplevelse av bivirkninger og 
førstegangsforverringer i forbindelse med behandlingen de fikk hos homeopaten. I denne 
sammenhengen er det viktig og skille mellom bivirkninger og førstegangsforverringer av det 
homeopatiske middelet.
Så langt viser forskning at bivirkninger opptrer i ca 2-3 % av tifellene ved homeopatisk 
behandling. Førstegangsforverringer er rapportert i alt fra 10-70% i klinisk praksis. 
Invitasjon
I den forbindelse vil vi intervjue 10 homeopater for å spørre dem om deres erfaringer med 
bivirkninger av homeopatisk behandling. Vi inviterer deg med dette til å delta i dette 
intervjuet. Gjennom intervjuet vil vi forsøke å finne mulige kriterier for hva som skiller disse
to fenomenene, og hvordan homeopatene i praksis avgjør når en førstegangsforverring går 
over til å bli en bivirkning. Intervjuet vil foregå i Oslo i løpet av februar/mars 2011. Vi vil 
komme tilbake til sted og dato senere.
Fokusgruppe intervju
Vi vil arrangere to fokusgruppe-intervjuer, med 5 homeopater i hver gruppe. Intervjuet vil bli 
tatt opp på lydbånd, for senere å bli transkribert. Alle deltagerne vil bli anonymisert. Hvert
gruppe- intervju vil vare mellom en til to timer. Intervjuet vil foregå som en samtale mellom 
deltagerne, men forskningslederen vil legge inn noen føringer slik at vi hele tiden er fokusert 
på de tema som skal belyses. Derfor vil vi be deg om å tenke over følgende:
Bivirkninger
Hvilke erfaringer har du med bivirkninger av homeopatisk behandling?
Hvor ofte erfarer du bivirkninger i klinisk praksis.? Hva gjør du da?
Hvilke rutiner har du hvis/ når det oppstår en slik situasjon? Hvordan informerer du 
pasientene dine?
Er det noen sykdommer/lidelser som lettere gir bivirkninger enn andre?
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Er det noen homeopatiske midler som fremkaller dette hyppigere enn andre?
Hvordan avgjør du om symptomene pasientene får etter behandling er bivirkninger 
eller førstegangsforverringer.
Førstegangsforverringer
Hvilke erfaringer har du med førstegangsforverring av homeopatisk behandling?
Informerer du alltid/noen ganger/aldri om at pasientene kan få en 
førstegangsforverring og at dette er en naturlig del av behandlingen?
Hvor ofte opplever du at pasientene får en førstegangsforverring?
Hvilke rutiner har du i klinisk praksis som informerer pasienten om dette fenomenet?
Er det noen lidelser hvor du ser førstegangsforverringer hyppigere enn andre?
Er det noen homeopatiske midler som gir sterkere førstegangsforverringer? 
Praktisk
Gi beskjed til Trine Stub via e-post, så bestiller NAFKAM flybillett tur- retur Oslo og 
sender den til deg på e-post. Hvis du må ta buss eller tog så ta vare på billettene så får du 
refusjon av dine utgifter.
Vi mener denne forskningen er viktig for å sikre pasientsikkerheten ved homeopatisk 
behandling. Den er også med på å kvalitetssikre homeopatien som medisinsk system.  
Samtidig er den en del av doktorgradsarbeidet til Trine Stub.
Forskningsprosjektet blir støttet av NHL og håper at du vil delta på dette.
Har du noen spørsmål så kontakt meg på e-post eller telefon: 77 64 92 86
Svarfrist 24. januar
Vennlig hilsen Trine Stub
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Fokusgruppe intervju med homeopater om førstegangsforverringer av 
homeopatisk medisin og Bivirkninger
Introduksjon
1. Velkommen
God formiddag alle sammen. Tusen takk for at dere tok dere tid til å komme til dette 
gruppe intervjuet i dag [1]. Mitt navn er Trine Stub, jeg er stipendiat ved NAFKAM 
(Nasjonalt forskningssenter innen alternativ og komplementær medisin). Jeg er utdannet 
homeopat ved NAN kull III (tror jeg) og har jobbet i privat praksis først i Porsgrunn og så 
på Statelle siden 1985 (26år).
Jeg har med meg Terje Alræk som er seniorforsker på NAFKAM, og min veileder i dette 
prosjektet som er en del av mitt doktorgradsarbeid om homeopati og sikkerhet. Han skal 
være observatør og ordne det tekniske det vil si båndopptakeren. Han vil presentere seg 
nærmere når vi skal ta en presentasjonsrunde senere.
Vi ønsker å høre om deres erfaringer med homeopatisk førstegangsforverringer. Vi vil 
gjerne at dere forteller oss hvilke erfaringer dere har med dette fenomenet fra praksis. Vi 
vil også drøfte, ut i fra deres erfaringer, om homeopatisk behandling har noen 
bivirkninger. Her vil jeg gjerne presisere at vi ikke skal komme frem til mulig prevalens 
(utbredelse) av bivirkninger. Men at vi skal gjøre et fagutviklings arbeid hvor vi skal 
forsøke å skille disse to begrepene fra hverandre basert på deres erfaringer.
Vi har valgt ut dere fordi dere har vært i klinisk praksis i mange år og derfor har praktisk 
erfaring med disse tingene, som vi nå ønsker og utdype.
Jeg vil dere skal vite at det er ingen svar som er feil, men heller forskjellige synspunkter
og erfaringer om disse to fenomenene.  Føl dere fri til å si hva dere mener selv om det er 
forskjellig fra hva andre mener. Vi er interessert i alle kommentarer og husk at vi gjerne 
vil ha frem alles synspunkter.
2. Innføring i emnet. Hvorfor er dere her
I dag vil vi diskutere og utveksle tanker, meninger og praktiske erfaringer som dere har 
med førstegangsforverringer og bivirkninger, for deretter forsøke å komme frem til mulige 
kriterier som skiller disse fra hverandre (fagutvikling). Det vi kommer frem til her vil bli 
lagt frem for en internasjonal gruppe av homeopater der vi vil forsøke å komme til enighet 
om disse kriteriene. 
3. Kjøreregler i diskusjonen
Før vi starter, la meg foreslå noen ting som vil gjøre diskusjonen mer produktiv. Vær så 
snill og ta ordet og ikke vær sjenert, men bare en person bør snakke om gangen. Vi vil ta 
opp dette intervjuet slik at vi ikke mister noen informasjon. Vi er på fornavn med hverandre




Min rolle her er å stille spørsmål og lytte. Jeg vil ikke delta i samtalen, men ønsker at dere 
skal snakke åpent med hverandre. Jeg vil stille dere noen spørsmål og lede diskusjonen fra 
spørsmål til spørsmål. Det er ofte en tendens i en gruppe til at noen snakker mye og andre 
snakker lite. Men det er viktig at vi hører alles stemme her i dag fordi dere har forskjellige 
erfaringer. Så hvis det er noen som har mye å dele mye med oss må jeg be deg om at man 
lar andre også komme til ordet. Og hvis du ikke snakker så mye spør jeg om din mening 
også.
4.   Hvorfor er denne forskningen viktig?
Hvorfor er denne forskningen er viktig. Fordi den er etterspurt i fagmiljøet (British 
Journal of Homeopathy). Og fordi den er med på å kvalitetssikre homeopatien. Den er 
også en måte å utvikle faget på. Samtidig er den viktig for pasientsikkerheten og at
myndighetene og helsearbeidere inkludert homeopater kan si noe om sikkerheten ved 
homeopatisk behandling som er basert på forskningen. NHL synes også denne 
forskningen er viktig, og har derfor støttet dette prosjektet med 30 000 kr fordelt over tre 
år.
5. Definisjon av begrepene
Dele ut et ark med definisjonene på. I tillegg kortet mitt og reflekser fra NAFKAM (bra
med en aktivitet)
Jeg har sent disse definisjonene til dere på e-post og bedt om at dere kommenterer dem og 
dette er resultatet. Jeg synes det er viktig at vi går raskt igjennom dem slik at vi alle snakker 
om det samme.
Førstegangsforverring. Både Hahnemann, Kent og Vithoulkas og mange andre store navn
innen homeopatien har definert begrepet. Personlig bruker jeg denne definisjonen:
Homeopatisk førstegangsforverring defineres som en forverring av pasientens 
eksisterende eller tidligere symptomer (som nødvendigvis ikke er tilstede under 
førstegangskonsultasjonen) og som bryter ut kort tid etter at man har tatt homeopatisk 
medisin [2]. En slik reaksjon er midlertidig, og blir ansett som en positiv reaksjon som 
indikerer at en lindrende prosess er satt i gang [3]. Reaksjonen etterfølges av at 
symptomene forblir som før eller av en bedring av symptomene [2]. De fleste homeopater 
hevder å ha observert slike reaksjoner i klinisk praksis [4-6].
Faglitteraturen rapporterer at førstegangsforverringer opptrer i alt fra 10 % til 75 % [7] [8]
i klinisk praksis.
Bivirkning
Her bruker jeg definisjonen baser på Statens legemiddelkontroll sin definisjon.
Som bivirkning regnes alle sykdommer eller uønskede og / eller skadelige reaksjoner som 
oppstår i undersøkelsestiden, uansett sammenhengen med foreskreven behandling.
For å avgjøre om det er sammenheng med behandlingen brukes tilgjengelig data/opplysninger 





Ikke mulig å vurdere
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Her bruker man tidskriterier for å avgjøre om det er en sammenheng eller ikke.
Som Alvorlige bivirkning regnes bivirkninger som medfører død, livstruende sykdom, 
vedvarende betydelig nedsatt funksjonsevne eller funksjonskapasitet, sykehusinnleggelse eller 
forlenget sykehusopphold.
Intensitet
Milde: ingen påvirkning av daglig aktivitet
Moderate: påvirkning av daglig aktivitet
Kraftige: ikke i stand til å utføre daglig aktivitet
Proving symptomer
Proving symptomer er symptomer pasienten får av et homeopatisk middel som enten er blitt 
gitt for hyppig og/eller over for lang tid, i en feil fortynning til sensitive personer. Pasienten 
får symptomer som ligner de symptomene middelet er ment å kurere (ifølge likhetsloven). 
Proving: Is the effect caused to the patient by a too frequent ill-timed repetition of the remedy 
causing pathogenic symptoms of the same remedy that are produced in pure experimentation 
[9].
6. Presentasjon av gruppemedlemmene:
Jeg vil jeg gjerne at dere presenterer dere for gruppa. Vi starter med å ta en runde rundt 
bordet.
7. Åpningsspørsmålet
Fortell oss hvem du er, hvor du har praksis og hvor mange år du har vært i praksis. Først vil 
Terje Alræk presentere seg selv.
Da starter jeg med et spørsmål om førstegangsforverringer.                           
Førstegangsforverringer
1. Hvor ofte opplever du i din praksis at pasientene dine rapporterer om 
førstegangsforverringer?
2. Informerer du dine pasienter om at dette kan skje, i så fall hvordan informerer du om
dette?
3. Litteraturen hevder at det er forskjell på førstegangsforverringene til pasienter som 
kommer med en 
a) akutt lidelse (kort tid etter inntak av medisinen, og varer bare fra noen timer til en kveld) i 
forhold til en
b) kronisk lidelse (forverring av eksisterende symptomer samt oppblomstring av tidligere 
symptomer, kommer ofte i løpet av de første 14 dagene, kan vare opp til en måned)
sammenlignet med pasient som kommer med en
c) kroniske lidelser med akutte topper (forverringene kommer ofte rundt administrasjon av 
middelet). Hvis vi antar at dette stemmer, kan dere ta to minutter å tenke litt over dette, så kan 
vi kanskje starte med forverringer hos pasienter som kommer med en akutt lidelse. Hvis dere 
trenger det ligger det papir og blyanter her på bordet.
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Nøkkelspørsmål
4. De førstegangsforverringene pasientene opplever er de alltid knyttet opp mot pasientens 
symptombilde, eller er det noen symptomer pasienten kan få som ikke er knyttet opp mot 
symptombilde? I så fall hvilke?  ( hodepine, tretthet). Kan dette i så fall være en mulig 
bivirkning?
5. Hvordan avgjør du om de forverringene pasienten forteller om, er førstegangsforverringer 
og ikke en naturlig forverring av sykdommen generelt?
6. Er det noen forandringer pasienten forteller deg om som kan si deg noe om hvilken vei 
dette går? Mot en bedring eller mot en fortsatt forverring? ( bedre psykisk, fysisk, mer energi, 
bedre søvn, ”Herings low of cure” eller andre ting?).
7. Som dere vet skal vi forsøke å komme frem til noen mulige kriterier som kan hjelpe 
homeopatene å differensiere mellom en førstegangsforverring og en bivirkning. Er det noe vi 
har diskutert så langt som kan bli mulige kriterier?
8. Er det noen homeopatisk midler som gir en sterkere førstegangsforandring enn andre 
midler?
9. Er det noen sykdommer/tilstander hvor førstegangsforverringer er hyppigere å se enn andre 
sykdommer?
Bivirkninger
1. Hvor ofte har du erfart at pasienter har rapportert til deg at de har fått bivirkninger av 
homeopatisk medisin?
2. Hvis det skulle skje, hva gjør du da? Hvilke rutiner har du?
3. Ber du pasienten kontakte lege? Hvis ja, i hvilke situasjoner ber du pasienten kontakte 
lege? Har det vært situasjoner der du før oppstart av behandlingen har sent pasienten til 
lege eller at du i ettertid (etter behandlingen) ser at du burde det? Hvis ja er det noen 
spesielle sykdommer / pasientgrupper som går igjen?
4. Har du erfart at pasienter får ”proving symptomer” av et middel. I tilfelle hvor ofte? I så 
fall hvilke symptomer var det?
5. Mener du at ”proving symptomer” kan sees på som mulige bivirkninger av homeopatisk 
medisin?
Nøkkel symptomer:
6. Vi vet jo alle som sitter her hvor vanskelig det kan være å finne det riktige homeopatiske 
middelet og ofte kan det være at pasienten trenger flere midler før man kommer i mål.  
Vithoulkas har i sin nye bok (Level of Health) beskrevet situasjoner hvor bivirkninger kan 
oppstå (også andre forskere Rossi /Thompson). Hvis det blir gitt:
a) et galt homeopatisk middel / et middel som er nært, men ikke helt perfekt match
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b) Riktig middel, men gal potens eller galt tids- intervall (for hyppig eller vente for 
lenge med å gi et nytt).
c) Seponering av skolemedisinsk behandling
d) Har med veldig sensitive personer å gjøre, eller med
e) Pasienter med svakt immunforsvar, så kan det oppstå mulige bivirkninger. Hvilke 
erfaringer har du med dette?
7. Er det noen symptomer/plager som går igjen hos de pasienter som rapporterer om mulige 
bivirkninger av behandlingen (her mener jeg plager som ikke er en del av 
førstegangsforverringen).
8. Hvordan avgjør du om de symptomene pasienten opplever etter homeopatisk medisin er 
en del av en lindrende prosess /førstegangsforverringer eller er mulige bivirkninger.
9. Ut i fra det vi har snakket om frem til nå, kan du se for deg noen kriterier som skiller 
mulige bivirkninger fra førstegangsforverringer?
10. Er det noen sykdommer hvor du ser mulige bivirkningen av behandlingen oftere enn andre 
sykdommer? ( ulcerøs colitis, morbus-chron, atopisk eksem, astma).
11. Er det noen midler som fremkaller mulige bivirkninger oftere enn andre? ( Silicea, Hepar-
sulph, Sulphur, Lachesis, Pulsatilla)
Avslutningsspørsmål
Hva synes du er det viktigste vi har diskutert her i dag?
8. Avslutning
Terje, vil du summere opp det viktigste vi har kommet frem til i dag?( to til tre minutter)
9. Etter oppsummeringen: 
Er dette en adekvat oppsummering. Dekker det alt som har blitt snakket om her i dag?
Er det noe vi skulle ha snakket om som vi ikke har diskutert?
10. Refleksjon over intervjuet: (hvis vi får liten tid, kan jeg sende dette på e-post etterpå)
Var dette en grei situasjon og snakke i?
Hva kunne vi ha gjort annerledes?
11. Hvordan skal intervjuet brukes videre
Som jeg var litt inne på i innledningen så er dette en del av et prosjekt om homeopati og 
sikkerhet. Det skal til sammen avholdes to gruppeintervjuer, hvorav dette er det første/andre 
intervjuet. Intervjuene skal nå transkriberes og skrives ut. Jeg kommer til å sende dere et 
utkast på det vi har kommet frem til, som dere kan kommentere, og som jeg eventuelt vil 
justere. Så sender vi det ut til en gruppe av internasjonale homeopater i en Delphi prosess 
[10]. Denne artikkelen som Terje har skrevet, beskriver hvordan dette vil foregå. (Deler ut 
artikkelen til Terje). Kort fortalt innebærer det flere e-post runder, hvor man til slutt skal 
komme til enighet om disse kriteriene som vi er på jakt etter.
Åpne opp for videre kontakt
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12. Debrifing etter intervjuet
1. Hva var de viktigste temaene/ideene/kriteriene som kom frem i diskusjonen?
2. Hvordan skiller de seg ut fra hva vi forventet?
3. Forskjeller mellom gruppene?
4. Hva skal vi ha med i artikkelen/ tesen
5. Hvilke sitater skal være med?
6. Var det noe uventet som ble belyst. Kom vi frem til noe nytt eller var det som 
forventet?
7. Skal vi gjøre noe annerledes i det neste intervjuet
Påminnelser til meg selv
Pause
Ta en pause og tenk over svaret. Vi venter til dere er klare til å svare
Hva mener dere andre om dette?  Andre meninger?
Det er ingen grunn til å forhaste seg, vi tar den tiden dere trenger
Fortell meg hvorfor det ikke er noe svar til dette spørsmålet
Underveis
Vær klar på hva som er fokuset for intervjuet (kriterier). Sammendraget skal dreie seg om det.
Notater med følgende i tankene: Et kort sammendrag samt notater for analysen etter 
intervjuet.
Start sammendraget med det som er viktigst
Skriv ned hva som ikke ble nevnt, men kanskje burde blitt det.
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Både Hahnemann, Kent og Vithoulkas og mange andre store navn innen homeopatien har 
definert begrepet. Jeg har valgt og bruker denne definisjonen [1].
Homeopatisk førstegangsforverring defineres som en forverring av pasientens eksisterende 
eller tidligere symptomer (som nødvendigvis ikke er tilstede under 
førstegangskonsultasjonen) og som bryter ut kort tid etter at man har tatt homeopatisk medisin 
[2]. En slik reaksjon er midlertidig, og blir sett på som en positiv reaksjon som indikerer at en
kurativ prosess er satt i gang [3]. Reaksjonen etterfølges av at symptomene forblir som før eller 
av en bedring av symptomene [2]. De fleste homeopater hevder å ha observert slike reaksjoner 
i klinisk praksis [4-6].
Faglitteraturen rapporterer at førstegangsforverringer opptrer i alt fra 10 % til 75 % [7] [8] i
klinisk praksis.
Bivirkning
Definisjonen er baser på Statens legemiddelkontroll sin definisjon.
Som bivirkning regnes alle sykdommer eller uønskede og / eller skadelige reaksjoner som 
oppstår i undersøkelsestiden, uansett sammenhengen med foreskreven behandling.
For å avgjøre om det er sammenheng med behandlingen brukes tilgjengelig data/opplysninger 





Ikke mulig å vurdere
Her bruker man tidskriterier for å avgjøre om det er en sammenheng eller ikke.
Som Alvorlige bivirkning regnes bivirkninger som medfører død, livstruende sykdom, 




Milde: ingen påvirkning av daglig aktivitet
Moderate: påvirkning av daglig aktivitet
Kraftige: ikke i stand til å utføre daglig aktivitet
Proving symptomer
Proving symptomer er symptomer pasienten får av et homeopatisk middel som enten er blitt 
gitt for hyppig og/eller over for lang tid, i en feil fortynning til sensitive personer. Pasienten 
får symptomer som ligner de symptomene middelet er ment å kurere (ifølge likhetsloven). 
Proving: Is the effect caused to the patient by a too frequent ill-timed repetition of the remedy 
causing pathogenic symptoms of the same remedy that are produced in pure experimentation 
[9].
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Kjære Lege og Homeopat
Ved NAFKAM (Nasjonalt forskningssenter innen alternativ og komplementær medisin), er vi 
i gang med et forskningsprosjekt om homeopati og risiko. Blant annet holder vi på med en 
spørreundersøkelse blant pasienter som oppsøker homeopat for første gang, hvor vi spør dem 
om deres erfaringer og reaksjoner etter homeopatisk behandlingen. Vi har også gjennomført 
to gruppe- intervjuer med klassiske homeopater, hvor vi har spurt dem om hvordan de skiller 
førstegangsforverringer fra bivirkninger av behandlingen. Tidligere forskning viser at 
bivirkninger opptrer i ca 2-3 % av tifellene ved homeopatisk behandling. 
Førstegangsforverringer er rapportert i alt fra 10-70% i klinisk praksis. Vi mener det vil være 
interessant å spørre leger som også er homeopater om hvilke erfaringer de har med risiko 
knyttet til klinisk praksis.
Invitasjon
Det er pr i dag bare en håndfull personer i Norge med samme bakgrunn som din egen. Vi 
mener du besitter en unik kompetanse og klinisk erfaring som det er viktig å forske på. I den 
forbindelse vil vi invitere deg til å delta i et fokusgruppe- intervju. Gjennom intervjuet vil vi 
forsøke å finne noen kriterier som skiller førstegangsforverringer fra bivirkninger og hvordan 
du i praksis avgjør når en førstegangsforverring går over til å bli en bivirkning. Intervjuet vil 
foregå i Oslo i slutten av november, eller i begynnelsen av desember 2011.
Fokusgruppe intervju
Vi vil arrangere to fokusgruppe- intervju, med 4 lege- homeopater i hver gruppe. Intervjuet vil 
bli tatt opp på lydbånd, for senere å bli transkribert. Alle deltagerne vil bli anonymisert. Hvert 
gruppe- intervju vil vare mellom en til to timer. Intervjuet vil foregå som en samtale mellom 
deltagerne, men forskningslederen vil legge inn noen føringer slik at vi hele tiden er fokusert 
på de tema som skal belyses.  Vi vil be deg om å tenke over følgende:
Bivirkninger
Hvilke erfaringer har du med bivirkninger av homeopatisk behandling?
Hvor ofte erfarer du bivirkninger i klinisk praksis.? Hva gjør du da?
Hvilke rutiner har du hvis/ når det oppstår en slik situasjon? Hvordan informerer du 
pasientene dine? 
Er det noen sykdommer/lidelser som lettere gir bivirkninger enn andre?
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Er det noen homeopatiske midler som fremkaller dette hyppigere enn andre?
Hvordan avgjør du om symptomene pasientene får etter behandling er bivirkninger 
eller førstegangsforverringer.
Førstegangsforverringer
Hvilke erfaringer har du med førstegangsforverring av homeopatisk behandling?
Informerer du alltid/av og til/aldri om at pasientene kan få en førstegangsforverring og 
at dette er en naturlig del av behandlingen?
Hvor ofte opplever du at pasientene får en førstegangsforverring?
Er det noen lidelser/ homeopatiske midler, hvor du ser førstegangsforverringer mer 
hyppig enn ved andre lidelser?
Andre tema vil være:
Erfaring med ”Doctor delay contact” (Forsinket kontakt med helsevesenet).
Hvordan er det for deg å tilhøre to medisinske paradigmer? 
Hva skiller disse to paradigmene og hva har de tilfelles?
Hva gjør det med deg som terapeut? Hvordan håndterer du dette i daglig praksis?
Hva er etter din mening det unike med homeopatien som medisinsk system?
Praktisk
Intervjuene skal holdes i Oslo. Vi kommer nærmere tilbake til hvor, når datoen er fastsatt. 
Vi håper å få til et intervju på fredag og et på lørdag. 
Følgende dato er aktuelle: fredag 18.11 eller fredag 25.11. eller fredag 02.12. Alle 
fredagene kl:17.30.
Lørdag 19.11. Lørdag 26.11. Lørdag 3.12. Alle lørdagene kl:12.00.
Fint om du svarer til Trine på e-post trine.stub@uit.no hvilke av disse datoene som passer
(så mange du kan). Vi dekker reiseutgifter samt servering du trenger underveis. Ta derfor
vare på kvitteringene. Det blir enkel servering under intervjuet..
Vi mener denne forskningen er viktig for å sikre pasientsikkerheten ved homeopatisk 
behandling. Den er også med på å kvalitetssikre homeopatien som medisinsk system. 
3
Dessuten er dette et fagutviklings prosjekt. Det er også en del av doktorgradsarbeidet til Trine 
Stub som er homeopat, akupunktør og forsker. Forskningsprosjektet blir støttet av NHL.
Vi håper at du ser nytten av denne forskningen hvor du også får gleden av å treffe kolleger 
med samme bakgrunn som deg selv. 
Har du noen spørsmål så kontakt Trine på e-post: trine.stub@uit.no
eller telefon: 77 64 92 86 eller mobil: 92 26 75 02
Forskningsgruppen består av: Trine Stub, Terje Alræk og Anita Salamonsen, alle forskere ved 
NAFKAM.
Hilsen, Trine Stub 
(på vegne av forskningsgruppen)
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Fokusgruppe intervju med lege- homeopater om homeopati og risiko                                
Introduksjon
1. Velkommen
God formiddag alle sammen. Tusen takk for at dere tok dere tid til å komme til dette 
intervjuet i dag [1]. Mitt navn er Trine Stub, jeg er stipendiat ved NAFKAM. Utdannet 
homeopat ved NAN kull III og akupunktør fra Norsk Akupunktur skole kull I. Jeg har en 
master i akupunktur fra Sydney og en Master i Folkehelsevitenskap fra Universitetet i 
Tromsø. Før jeg kom til Tromsø jobbet jeg i privat praksis først i Porsgrunn og så på 
Statelle i 23år.
Jeg har med meg Terje og Anita som er forskere på NAFKAM. Terje er min veileder i 
dette prosjektet som er en del av mitt doktorgradsarbeid om homeopati og sikkerhet. Anita 
har lang erfaring i bruk av intervjuer som forskningsmetode. Både Anita og Terje skal 
være observatører og senere bidra til artikkelen som skal skrives på bakgrunn av dagens 
intervju med dere. De skal også ordne det tekniske, det vil si båndopptakeren. De vil
presentere seg nærmere når vi skal ha en presentasjonsrunde senere. Før vi begynner vil 
jeg be dere om å fylle ut et skjema, så vi får litt informasjon om utdanning og den 
praksisen der har. ( Deler ut skjema).
Start
Vi ønsker å høre om deres erfaringer med homeopatisk førstegangsforverringer. Vi vil 
gjerne at dere forteller oss hvilke erfaringer dere har med dette fenomenet fra praksis. Vi 
vil også drøfte om homeopatisk behandling har noen bivirkninger. Vi vil også diskutere 
andre aspekter av risiko begrepet slik som ” Doctor deley contact”, om pasienter som 
bryter helt med helsevesenet utgjør en helserisiko, om interaksjon mellom legemidler 
og homeopatiske midler/urter og hvilke erfaringer dere har med å behandle sensitive
personer.
Vi har valgt ut dere fordi dere har vært i klinisk praksis som både lege og homeopat og 
som sådan besitter en unik kompetanse, derfor vil vi gjerne diskutere hvordan det er å 
tilhøre to medisinske paradigmer.
I et fokusgruppe- intervju som dette, er det ingen svar som er feil. Vi leter tvert i mot etter 
forskjellige synspunkter på og erfaringer med temaene som reises.  Føl dere fri til å si hva 
dere mener selv om det er forskjellig fra hva andre mener. Vi er interessert i alle kommentarer 
og husk at vi gjerne vil ha frem alles synspunkter. 
2. Kjøreregler i diskusjonen
Før vi starter, la meg foreslå noen ting som vil gjøre diskusjonen mer produktiv. Vær så snill 
og ta ordet og ikke vær sjenert, men bare en person bør snakke om gangen. Vi vil ta opp dette 
intervjuet slik at vi ikke mister noen informasjon. Vi er på fornavn med hverandre og i 
artikkelen som skal skrives senere vil vi ikke bruke navnene deres eller annen informasjon 
som kan identifisere dere. Slik sett sikrer vi deres anonymitet.
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Min rolle her er å stille spørsmål og lytte. Jeg vil ikke delta i samtalen, men ønsker at dere 
skal snakke åpent med hverandre. Jeg vil stille dere noen spørsmål og lede diskusjonen fra 
spørsmål til spørsmål. Det er ofte en tendens i en gruppe til at noen snakker mye og andre 
snakker lite. Men det er viktig at vi hører alles stemme her i dag fordi dere har forskjellige 
erfaringer. Så hvis det er noen som har mye å dele mye med oss må jeg be deg om at man lar 
andre også komme til ordet. Og hvis du ikke snakker så mye spør jeg deg om din mening 
også.
4.   Hvorfor er denne forskningen viktig?
Hvorfor er denne forskningen viktig? Fordi den er etterspurt i fagmiljøet (British Journal of 
Homeopathy). Og fordi den er med på å kvalitetssikre homeopatien. Den er også en måte å 
utvikle faget på og løfter frem, en i Norge, liten gruppe terapeuter, med en unik kompetanse 
innen to fagfelt. Samtidig er forskningen viktig for pasientenes sikkerhet og for at
myndighetene og andre i helsevesenet kan si noe om homeopatisk behandling som er basert 
på forskningen. NHL synes også denne forskningen er viktig, og har derfor støttet dette 
prosjektet med 30 000 kr.
5. Presentasjon av gruppemedlemmene:
Jeg vil jeg gjerne at dere presenterer dere for gruppa. Vi starter med å ta en runde rundt 
bordet.
6. Presentasjon av med forskere i prosjektet
Anita og Terje presenterer KORT seg selv
7. Åpningsspørsmålet
Fortell oss hvem du er og arbeidet ditt.
Da starter jeg med et spørsmål om førstegangsforverringer.                           
8. Førstegangsforverringer
Opplever du i din praksis at pasientene dine rapporterer om førstegangsforverringer i
så fall, hvor ofte?
Informerer du dine pasienter om at dette kan skje, i så fall hvordan informerer du om 
dette?
Nøkkelspørsmål
Hvordan avgjør du om de forverringene pasienten forteller om, er 
førstegangsforverringer og ikke en naturlig forverring av sykdommen generelt?
Er det noen forandringer pasienten forteller deg om som kan si deg noe om hvilken vei 
dette går? Mot en bedring eller mot en fortsatt forverring? ( bedre psykisk, fysisk, mer 
energi, bedre søvn, ”Herings low of cure” eller andre ting?).
”Doctor deley contact ” Pasienter som bruker homeopati, fordi de i noen tilfeller 
oppsøker lege senere enn de ellers ville ha gjort og som sådan kan den homeopatiske 
behandlingen utgjøre en helserisiko. Hvordan løser du dette?
9. Bivirkninger
Har du erfart at pasienter har rapportert til deg at de har fått bivirkninger av 
homeopatisk medisin?
Hvis det skulle skje, hva gjør du da? Hvilke rutiner har du?
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Nøkkel symptomer:
Vi vet jo alle som sitter her hvor vanskelig det kan være å finne det riktige homeopatiske 
middelet og ofte kan det være at pasienten trenger flere midler før man kommer i mål.  Har du 
opplevd at pasientene dine har fått bivirkninger av behandlingen hvis du har gitt
Et galt homeopatisk middel / potens eller tids intervall?
Seponering av skolemedisinsk behandling, eller ved interaksjon mellom skolemedisin 
og homeopatisk medisin.
”Highly sensitive persons” er kjent fra litteraturen, hvilke erfaringer har du med slike 
pasienter og hvordan behandler du dem?
Hvordan avgjør du om de symptomene pasienten opplever etter homeopatisk medisin 
er en del av en lindrende prosess /førstegangsforverringer eller er mulige bivirkninger.
Ut i fra det vi har snakket om frem til nå, kan du se for deg noen kriterier som skiller 
mulige bivirkninger fra førstegangsforverringer?
10. Pasienter som bryter helt med skolemedisinen
Noen pasienter bryter helt med skolemedisinen, hva synes/tenker du om det?
Utgjør bruddet med skolemedisinsk behandling en helse – risiko?
Hvorfor tror du pasienter velger å gå til deg som både er lege og homeopat?
11. Hvordan er det å tilhøre to medisinske paradigmer?
Hvordan vi du beskrive det skolemedisinske og alternativ medisinske paradigme? 
Likheter og forskjeller?
Hvordan forener du i din praksis disse to verdensbildene?
Hva gjør det med deg som terapeut?
Hvordan kommer dette dine pasienter til gode? ( risiko)
Er det noen ulemper for deg i din yrkesutøvelse å være utdannet innenfor begge disse 
paradigmene? (hvordan andre leger ser på en lege som er homeopat, evt også hvordan 
homeopater ser på homeopater som også er leger).
12. Kommunikasjon
Mange pasienter ønsker å snakke med terapeuten sin om problemer av eksistensiell 
karakter ofte knyttet til alvorlig sykdom, Hvordan gjør du dette?
Hvordan kan det homeopatiske intervjuet være med på å åpne opp for en slik 
Avslutningsspørsmål
Hva synes du er det viktigste vi har diskutert her i dag? kommunikasjon? Kan 
mangel på slik kommunikasjon være en helserisiko for pasientene? Hvordan og 
hvorfor?
8. Avslutning
Anita / Terje, vil du summere opp det viktigste vi har kommet frem til i dag?( to til tre 
minutter)
9. Etter oppsummeringen: 
Er dette en adekvat oppsummering. Dekker det alt som har blitt snakket om her i dag?
Er det noe vi skulle ha snakket om som vi ikke har diskutert?
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10. Refleksjon over intervjuet:
Var dette en grei situasjon og snakke i?
Hva kunne vi ha gjort annerledes?
11. Hvordan skal intervjuet brukes videre
Som jeg var litt inne på i innledningen så er dette en del av et prosjekt om homeopati og 
sikkerhet. Det skal til sammen avholdes to gruppeintervjuer, hvorav dette er det første/andre 
intervjuet. Intervjuene skal nå transkriberes og skrives ut. Analysen gjøres sammen med Anita 
og Terje. Jeg kommer til å sende dere et utkast på det vi har kommet frem til, som dere kan 
kommentere, og som jeg eventuelt vil justere. Når artikkelen er ferdig skrevet og publisert, 
sender jeg den til dere.
Åpne opp for videre kontakt
12. Debrifing etter intervjuet
1. Hva var de viktigste temaene/ideene/kriteriene som kom frem i diskusjonen?
2. Hvordan skiller de seg ut fra hva vi forventet?
3. Forskjeller mellom gruppene?
4. Hva skal vi ha med i artikkelen/ teksten
5. Hvilke sitater skal være med?
6. Var det noe uventet som ble belyst. Kom vi frem til noe nytt eller var det som 
forventet?
7. Skal vi gjøre noe annerledes i det neste intervjuet
Påminnelser til meg selv:
Pause
Ta en pause og tenk over svaret. Vi venter til dere er klare til å svare
Hva mener dere andre om dette?  Andre meninger?
Det er ingen grunn til å forhaste seg, vi tar den tiden dere trenger
Fortell meg hvorfor det ikke er noe svar til dette spørsmålet
Underveis
Vær klar på hva som er fokuset for intervjuet (kriterier). Sammendraget skal dreie seg om det.
Notater med følgende i tankene: Et kort sammendrag samt notater for analysen etter 
intervjuet.
Start sammendraget med det som er viktigst
Skriv ned hva som ikke ble nevnt, men kanskje burde blitt det.
Referanser
1. Rossi E, Bartoli P, Bianchi A, Endrizzi C, and Da Fré M, Homeopathic aggravation with 
Quintamillesimal Q (or LM) potencies. 2010, Homeopathic Clinic Local Health Authority 2: 
Lucca.
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Både Hahnemann, Kent og Vithoulkas og mange andre store navn innen homeopatien har 
definert begrepet. Jeg har valgt og bruker denne definisjonen [1].
Homeopatisk førstegangsforverring defineres som en forverring av pasientens eksisterende 
eller tidligere symptomer (som nødvendigvis ikke er tilstede under 
førstegangskonsultasjonen) og som bryter ut kort tid etter at man har tatt homeopatisk medisin 
[2]. En slik reaksjon er midlertidig, og blir sett på som en positiv reaksjon som indikerer at en
kurativ prosess er satt i gang [3]. Reaksjonen etterfølges av at symptomene forblir som før eller 
av en bedring av symptomene [2]. De fleste homeopater hevder å ha observert slike reaksjoner 
i klinisk praksis [4-6].
Faglitteraturen rapporterer at førstegangsforverringer opptrer i alt fra 10 % til 75 % [7] [8] i
klinisk praksis.
Bivirkning
Definisjonen er baser på Statens legemiddelkontroll sin definisjon.
Som bivirkning regnes alle sykdommer eller uønskede og / eller skadelige reaksjoner som 
oppstår i undersøkelsestiden, uansett sammenhengen med foreskreven behandling.
For å avgjøre om det er sammenheng med behandlingen brukes tilgjengelig data/opplysninger 





Ikke mulig å vurdere
Her bruker man tidskriterier for å avgjøre om det er en sammenheng eller ikke.
Som Alvorlige bivirkning regnes bivirkninger som medfører død, livstruende sykdom, 




Milde: ingen påvirkning av daglig aktivitet
Moderate: påvirkning av daglig aktivitet
Kraftige: ikke i stand til å utføre daglig aktivitet
Proving symptomer
Proving symptomer er symptomer pasienten får av et homeopatisk middel som enten er blitt 
gitt for hyppig og/eller over for lang tid, i en feil fortynning til sensitive personer. Pasienten 
får symptomer som ligner de symptomene middelet er ment å kurere (ifølge likhetsloven). 
Proving: Is the effect caused to the patient by a too frequent ill-timed repetition of the remedy 
causing pathogenic symptoms of the same remedy that are produced in pure experimentation 
[9].
Referanser
1. European Council for Classical Homeopathy. The Safety of Homeopathy An ECCH 
Report. In: European Council for Classical Homeopathy; 2009:1-35
2. Thompson E, Barron S, Spence D. A preliminary audit investigating remedy reactions 
including adverse events in routine homeopathic practice. Homeopathy 2004;93:203-
209
3. Endrizzi C, Rossi E, Crudeli L, Garibaldi D. Harm in homeopathy: Aggravations, 
adverse drug events or medication errors? Homeopathy 2005;94:233-240
4. Popova T. Homeopathic aggravations
Br Hom J 1991;80:228-229
5. Logan R. The Homeopathic Treatment of Eczema. Beaconsfield, Bucks: Beaconsfield 
Publishers LTD; 1998
6. Owen D. Principles and practice of Homeopathy. The Therapeutic and Healing 
Process. London: Churchill Livingstone Elsevier; 2007
7. Grabia S, Ernst E. Homeopathic aggravations: a systematic review of randomised, 
placebo-controlled clinical trials. Homeopathy 2003;92:92-98
8. Paterakis S, Bachas I, Vithoulkas G. Statistical data on aggravation after the 
similimum. Hahnemann Homeopathic Sand 1990;14:155-159
9. Rossi E, Bartoli P, Bianchi A, Endrizzi C, Da Fré M. Homeopathic aggravation: 
Quintamillesimal, Q (or LM), potencies. Homeopathy 2010;in manuscript
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b) Information and consent letter to children 

NAFKAM • Det helsevitenskaplige fakultet  • Universitetet i Tromsø • 9037 Tromsø 
nafkam@helsefak.uit.no • http://nafkam.no • Tlf: 77 64  66 50 • Faks: 77 64 68 66 
PhD stipendiat Trine Stub • trine.stub@uit.no • Tlf: 77 64 92 86  
Forespørsel om å delta i forskningsprosjekt 
 
PASIENTSIKKERHET VED HOMEOPATISK BEHANDLING 
Informasjon til personer under 16 år 
 
Bakgrunn  
Vi spør deg om å delta i en spørreundersøkelse om homeopati ved Universitetet i Tromsø. I denne 
undersøkelsen skal vi undersøke om homeopati har bivirkninger eller gir andre reaksjoner. Det vil si 
en virkning av behandlingen som ingen ønsker. Vi vet fra undersøkelser i utlandet at homeopati gir få 
bivirkninger, men vi vet ikke om dette stemmer med norske forhold. Derfor spør vi deg som er under 
16 år og som har vært hos homeopat for dine plager, om å delta i denne spørreundersøkelsen. 
 
Hva innebærer det å delta i prosjektet? 
Hos homeopaten vil du få en konvolutt som inneholder et spørreskjema som du skal svare på. Etter 
seks måneder vil du få tilsendt det samme spørreskjemaet en gang til. Det må også fylles ut og sendes 
til oss. Svarkonvolutt er lagt med. Svarene du sender, blir lest og analysert av forskerne. Forskerne får 
ikke vite hva du har snakket med homeopaten om, og homeopaten får heller ikke vite noe om dine 
svar.  
 
Hva skjer med informasjonen om deg? 
Navnet ditt og spørreskjemaet vi får fra deg blir koblet til en tallkode. Tallkoden blir koblet til en 
navneliste slik at vi kan finne igjen navnet ditt og adressen din. Disse opplysningene blir låst inn i et 
skap, og bare vi forskere kan låse opp skapet. Svarene vi får fra spørreskjemaene vil bli brukt til å skrive 
artikler. Artiklene blir publisert, og ingen kan koble deg og de svarene du har gitt i spørreskjemaet til 
det vi skriver om i artiklene.  
 
Må du delta i prosjektet? 
Nei. Det er frivillig å delta og du kan trekke deg uten å oppgi noen grunn for det. Men det vil være til 
stor hjelp for oss hvis du blir med.  
 
Hvis du har lyst til å være med i prosjektet, ber vi deg skrive under med navn og dato. Siden du er 
under 16 år, må dine foreldre/foresatte også skrive under på denne. Vennligst returner dette sammen 
med spørreskjemaet. 
 






Jeg vil være med i forskningsprosjektet 
 
………………… ………………………………………………………………. 
Dato   Navn  
 
Bekreftelse fra foreldre/foresatte 
 
………………… ………………………………………………………………. 




c) Information and consent letter to adults 

NAFKAM • Det helsevitenskaplige fakultet  • Universitetet i Tromsø • 9037 Tromsø 
nafkam@helsefak.uit.no • http://nafkam.no • Tlf: 77 64  66 50 • Faks: 77 64 68 66 
PhD stipendiat Trine Stub • trine.stub@uit.no • Tlf: 77 64 92 86  
Forespørsel om å delta i forskningsprosjekt 
 




Vi spør deg om å delta i en spørreundersøkelse om homeopati ved Universitetet i Tromsø. I denne 
undersøkelsen skal vi undersøke om homeopati har bivirkninger eller gir andre reaksjoner. Det vil si 
en virkning av behandlingen som ingen ønsker. Vi vet fra undersøkelser i utlandet at homeopati gir få 
bivirkninger, men vi vet ikke om dette stemmer med norske forhold. Derfor spør vi deg som har vært 
hos homeopat for dine plager, om å delta i denne spørreundersøkelsen. 
 
Hva innebærer det å delta i prosjektet? 
 Hos homeopaten vil du få en konvolutt som inneholder et spørreskjema som du skal svare på. Etter 
seks måneder vil du få tilsendt det samme spørreskjemaet en gang til. Det må også fylles ut og sendes 
til oss. Svarkonvolutt er lagt med. Svarene du sender, blir lest og analysert av forskerne. Forskerne får 
ikke vite hva du har snakket med homeopaten om, og homeopaten får heller ikke vite noe om dine 
svar.  
 
Hva skjer med informasjonen om deg? 
Navnet ditt og spørreskjemaet vi får fra deg blir koblet til en tallkode. Tallkoden blir koblet til en 
navneliste slik at vi kan finne igjen navnet ditt og adressen din. Disse opplysningene blir låst inn i et 
skap, og bare vi forskere kan låse opp skapet. Svarene vi får fra spørreskjemaene vil bli brukt til å skrive 
artikler. Artiklene blir publisert, og ingen kan koble deg og de svarene du har gitt i spørreskjemaet til 
det vi skriver om i artiklene.  
 
Må du delta i prosjektet? 
Nei. Det er frivillig å delta og du kan trekke deg uten å oppgi noen grunn for det. Men det vil være til 
stor hjelp for oss hvis du blir med.  
 
Hvis du har lyst til å være med i prosjektet, ber vi deg skrive under med navn og dato. Vennligst 
returner dette sammen med spørreskjemaet. 
 










Dato   Navn  
 
 







Spørsmål om reaksjoner etter behandling hos homeopat
Dette spørreskjemaet er en del av et forskningsprosjekt som skal undersøke pasientsikkerhet ved 
behandling hos homeopat.
Vi har spurt 200 homeopater om å gi dette spørreskjemaet til pasientene sine. Derfor mottar du dette  
spørreskjemaet i forbindelse med ditt besøk hos homeopaten. 
Vi mottar ingen informasjon om deg fra homeopaten, så spørreskjemaet er fullstendig anonymt. 
Det er helt frivillig å være med i denne undersøkelsen. Vi håper likevel at du vil ta deg tid til å svare slik at vi 
får opplysninger fra tilstrekkelig antall personer til å kunne fullføre dette forskningsprosjektet. 
Vennligst returner dette skjemaet i vedlagt konvolutt uansett om du har fylt det ut eller ikke.
    Jeg ønsker ikke å delta.
FYLLES UT AV HOMEOPATEN
Dato for pasientens første konsultasjon:            (dag/mnd/år)
FYLLES UT AV PASIENTEN
NB! Fylles ut ca. 14 dager etter du har begynt med homeopatisk medisin.
NAFKAM - NASJONALT FORSKNINGSSENTER INNEN KOMPLEMENTÆR OG ALTERNATIV MEDISIN
5)  Nåværende yrke / virksomhet:
        
6)  Yrkesaktiv:            Ja         Nei 
      Hvis ja: Heltid/deltid (prosent):   
7)  Attføring:        Ja      Nei   Tidsrom:   
8)  Uføretrygdet:        Ja      Nei
      Tidsrom:                     Helt/delvis (prosent): 
9)  Arbeidsledig:        Ja      Nei   Tidsrom:   
10) Pensjonist:        Ja      Nei   Tidsrom:   
Merknader spørsmål 5-10: 
       
12) Din høyeste fullførte utdannelse:




Høyskole / Universitet inntil 4 år
Høyskole / Universitet mer enn 4 år
11) Sivilstand:
Enslig
Gift / samboer / registrert partner
Skilt / separert
Enke / enkemann
Bor med to foreldre (gjelder barn)
Bor med én forelder (gjelder barn)
Bor vekselvis hos foreldrene (gjelder barn)
Bor med andre enn foreldrene (gjelder barn)
BAKGRUNNSINFORMASJON OM DEG 
3)        Mann             Kvinne   
4)  Fødselsår:
1)  Oppstart på medisin:                      (dag/mnd/år)
2)  Dato i dag:                                     (dag/mnd/år)
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Var ikke i stand til å  
utføre daglig aktivitet
Plage / sykdom 1:
Plage / sykdom 2:
Plage / sykdom 3:
17. I hvor stor grad påvirket plagen / sykdommen din daglige aktivitet FØR du oppsøkte homeopat?
         Ingen oppfordring fra homeopaten om å endre bruk av medisinen(e).
         Homeopaten oppfordret deg til å ta dette opp med legen din for eventuelt å redusere eller endre bruk av     
         medisinen(e).
         Homeopaten oppfordret deg til å redusere eller endre bruk av medisinen(e).
         Homeopaten tok ikke dette opp med deg.
16. Hva var homeopatens råd til deg om denne medisinbruken? 
Ja Nei Hvis ja, skriv navnet på medisinen her:
Plage / sykdom 1:
Plage / sykdom 2:
Plage / sykdom 3:
15. Bruker du eller har du brukt medisiner foreskrevet av lege for plagen / sykdommen?
Skriv antall og sett et kryss Antall dager måneder år
Plage / sykdom 1:
Plage / sykdom 2:
Plage / sykdom 3:
14. Hvor lenge har du hatt plagen / sykdommen?




Ikke i stand til å utføre 
daglig aktivitet
Plage / sykdom 1:
Plage / sykdom 2:
Plage / sykdom 3:
18. I hvor stor grad påvirker plagen / sykdommen din daglige aktivitet I DAG?
Plage / sykdom 1:
Plage / sykdom 2:
Plage / sykdom 3:
13. Hvilke plage / sykdom oppsøkte du homeopaten for?
      Bruk egne ord og skriv opptil tre plager her: 
3
     Ja  Nei Vet ikke
1e) Var reaksjonen slik at du fikk sterkere plager enn det du bruker å ha?
         Tok medisin / homeopatisk middel - Skriv hva du tok her:
         Oppsøkte lege
         Sov / hvilte / slappet av
         Trente / gikk tur / mosjonerte
        Annet, hva gjorde du?  
        Skriv her:
1f) Var reaksjonen av en slik art at du gjorde noe for å dempe den?          Ja         Nei
       Hvis ja, hva gjorde du? u kan sette ere kryss
1g) Knyttet du reaksjonen til medisin homeopaten gav deg?      Ja  Nei Vet ikke
Hvis ja, beskriv kort:
          Skriv antall timer / dager/ uker Antall  timer
Antall  dager
Antall  uker
 1c)  Hvor lang tid etter at du tok homeopatisk medisin kom reaksjonen?
1b) Hvor lenge varte reaksjonen?   
                                                                             Antall timer
Antall dager
Antall uker
Skriv antall timer / dager/ uker
1d) Hvordan påvirket reaksjonen  din 
       daglige aktivitet?




Var ikke i stand til å 
utføre daglig aktivitet
1a) Hva opplevde du / hva var reaksjonen?
        Skriv her:
Reaksjon 1
REAKSJONER
Vi er interessert i hvilke reaksjoner du har hatt i tiden etter at du tok homeopatisk medisin. Vi ber deg om å 
skrive ned alle reaksjoner, uansett hva du mener grunnen til reaksjonene kan være.  
Vi har satt av plass til å beskrive to reaksjoner i spørreskjemaet. Legg ved ekstra ark hvis du har ere  
reaksjoner eller trenger mer plass.
 Jeg har ikke hatt noen reaksjoner. Da kan du stoppe her, takk for din tid og  hjelp!
4
Takk for din tid og hjelp!
Vennligs returner dette skjemaet i vedlagt konvolutt uansett om du har fylt det ut eller ikke.
Trine Stub, PhD stipendiat
Terje Alræk,  Seniorforsker 
Jianping Liu, Seniorforsker 
Marja Verhoef, Seniorforsker
NAFKAM - NASJONALT FORSKNINGSSENTER INNEN KOMPLEMENTÆR OG ALTERNATIV MEDISIN
     Ja  Nei Vet ikke
2e) Var reaksjonen slik at du fikk sterkere plager enn det du bruker å ha?
         Tok medisin / homeopatisk middel - Skriv hva du tok her:
         Oppsøkte lege
         Sov / hvilte / slappet av
         Trente / gikk tur / mosjonerte
        Annet, hva gjorde du?  
        Skriv her:
2f) Var reaksjonen av en slik art at du gjorde noe for å dempe den?          Ja         Nei
       Hvis ja, hva gjorde du? u kan sette ere kryss
2g) Knyttet du reaksjonen til medisin homeopaten gav deg?      Ja  Nei Vet ikke
Hvis ja, beskriv kort:
          Skriv antall timer / dager/ uker Antall  timer
Antall  dager
Antall  uker
 2c)  Hvor lang tid etter at du tok homeopatisk medisin kom reaksjonen?
2b) Hvor lenge varte reaksjonen?   
                                                                             Antall timer
Antall dager
Antall uker
Skriv antall timer / dager/ uker
2d) Hvordan påvirket reaksjonen  din 
       daglige aktivitet?




Var ikke i stand til å 
utføre daglig aktivitet
2a) Hva opplevde du / hva var reaksjonen?
        Skriv her:
Reaksjon 2
Appendix 20.3 
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Questions about reactions following homeopathic treament
This questionnaire is part of a research project with the aim of analyzing patient safety 
connected to homeopathic treatment.
We have asked 200 homeopaths to give this questionnaire to their patients. That is why your 
homeopath has given you this questionnaire.
We receive no personal information from your homeopath, which ensures you complete 
confidentiality.
Participation is voluntary. Nevertheless, we hope that you will take your time answering the 
questions, so that we get information from an adequate number of people who will enable us 
to complete our research project.
Please return this questionnaire in the reply envelope enclosed, regardless of whether you 
have answered the questions.
I don´t want to participate.
TO BE COMPLETED BY THE HOMEOPATH
The date of the patient´s first consultation (date/month/year)
TO BE COMPLETED BY THE PATIENT
NOTE: To be completed 14 days after you started on homeopathic medication.
1) Started on medication:             (date/month/year)
2) Today´s date: (date/month/year)
PERSONAL DATA
3)     Male Female Boy younger than 18             Girl younger than 18
4) Year of birth:
5) Present occupation:
6) Do you work?         Yes      No
If yes: Full time/Part time (percent) _________
7) Rehabilitation: Yes No Period:
8) Disabled: Yes No
Period: Fully/Partly (percent)
Appendix 20.3.e
9) Unemployed Yes No Period:
10) Retired Yes No Period:






Living with two parents (for children)
Living with one parent (for children)
Living with both parents alternately (for children)
Living with other than the parents (for children)
12) Your highest level of education completed
Less than 7 years of primary school
7 years of primary school
Lower secondary school
Upper secondary school/Vocational school
Highschool/University, maximum 4 years
Highschool/University, more than 4 years
13. Give and account of the kind of illness/disease that made you see the homeopath. In 




14. For how long have you suffered from this illness/disease?
List the number and check one of the boxes




15. Do you use or have you used medication for your illness/disease prescribed by a 
doctor?




16. What kind of advice did the homeopath give you regarding this medication?
No advice from the homeopath on changing the use of the medication(s).
The homeopath adviced you to discuss this matter with your doctor with the aim of 
possibly reducing or changing the use of the medication(s).
The homeopath adviced you to reduce or change the use of the medication(s).
The homeopath did not discuss this matter with you.
17. To what extent did the illness/disease affect your daily activities PRIOR TO seeing the 
homeopath? 
Indicate using a number on a scale from 1 to 4 where 1= No influence of daily 




18. To what extent does the illness/disease affect your PRESENT daily activities?
Indicate using a number on a scale from 1 to 4 where 1= No influence of daily 





We are interested in knowing what kind of reactions you have experienced after having taken 
homeopathic medication. Please note all kinds of reactions, regardless of your own opinion 
about the cause. 
This questionnaire allows for description of two different kinds of reactions. Please add an 
extra sheet of paper if you have experienced additional reactions, or if you need more space.
I have not experienced any reaction. You have completed the questionnaire. Thanks
for your help!
Reaction 1
1a) What did you experience/What was the reaction? 
Give a brief description
1b) For how long did the reaction last?
List the number of hours/days/weeks: hours
days
weeks
1c) After you had taken the homeopathic medication, how long did it take before you 
experienced the reaction?
List the number of hours/days/weeks: hours
days
weeks
1d) How did the reaction affect your daily life?
Indicate using a number on a scale from 1 to 4 where 1= No influence of activities, and 4 =
Unable to perform daily activities.
1e) Did the reaction cause more symptoms than what you consider to be normal?
Yes No Don´t know
1f) Did you do anything to lessen the reaction? Yes    No
If yes, what did you do? You may choose more than one option.
I took medication/homeopathic remedy – please note what you took:
I visited my doctor
I slept/relaxed/calmed down
I exercised/went trudging/went for a walk
Anything else, what did you do?
Give a brief description.
1g) Did you connect the reaction to the homeopathic medication?
If yes, give a brief description. Yes   No   Don´t know
Reaction 2
2a) What did you experience/What was the reaction?
Give a brief description.
2b) For how long did the reaction last?
State the number of hours/days/weeks: hours
days
weeks
2c) After you had taken the homeopathic medication, how long did it take before you 
experienced the reaction?
State the number of hours/days/weeks: hours
days
weeks
2d) How did the reaction affect your daily life?
No effect Some effect Unable to perform daily activities
2e) Did the reaction cause more pain than what you consider to be normal?
Yes No Don´t know
2f) Did you do anything to lessen the reaction? Yes    No
If yes, what did you do? Du may choose more than one option.
I took medication/homeopathic remedy – please note what you took:
I visited my doctor
I slept/relaxed/calmed down
I exercised/went trudging/went for a walk
Anything else, what did you do?
Give a brief description.
2g) Did you connect the reaction to the homeopathic medication?
If yes, give a brief description. Yes   No   Don´t know
Thanks for your help!
Please return this questionnaire in the reply envelope enclosed, regardless of whether you 
have answered the questions.
Trine Stub, PhD candidate
Terje Alræk, Senior researcher
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Region: Saksbehandler: Telefon: Vår dato: Vår referanse:
REK nord Øyvind Strømseth 77620753 19.09.2011 2010/3379/REK nord
Deres dato: Deres referanse:
Terje Alræk
Forskningsparken








All post og e-post som inngår i
saksbehandlingen, bes
adressert til REK nord og ikke til
enkelte personer
Kindly address all mail and
e-mails to the Regional Ethics
Committee, REK nord, not to
individual staff
 Vedr.: Pasientsikkerhet ved behandling hos homeopat
Viser til vedtak av 15.4.2011. Ved en feil ble godkjennelsen gitt til 1.11.2011, det riktige skulle være
15.8.2013. Dette er rettet opp nedenfor, og dette vedtaket trer i stede for vedtak av 15.4.2011.
         Pasientsikkerhet ved behandling hos homeopat.
Vi viser til tilbakemelding av 29.3.2011 vedlagt forespørsel. 
I forespørselen er det inntatt følgende setning: ”Svarer du på, og sender inn begge spørreskjemaene vil du
være med i en utlodning av en iPad touch 32gb.” Dette er ikke tidligere omhandlet i søknaden og ordningen
kan derfor ikke aksepteres. Setningen må fjernes fra forespørselen.
 Etter fullmakt er det fattet slikt
 Vedtak:
 Med hjemmel i helseforskningsloven § 10 og forskningsetikkloven § 4 godkjennes prosjektet.
 Før prosjektet kan igangsettes må det sendes inn revidert informasjonsskriv i tråd med komiteens
merknader.
 Godkjenningen er gitt under forutsetning av at prosjektet gjennomføres slik det er beskrevet i søknaden og
protokollen, og de bestemmelser som følger av helseforskningsloven med forskrifter.
 Dersom det skal gjøres endringer i prosjektet i forhold til de opplysninger som er gitt i søknaden, må
prosjektleder sende endringsmelding til REK. Vi gjør oppmerksom på at hvis endringene er vesentlige, må
prosjektleder sende ny søknad, eller REK kan pålegge at det sendes ny søknad.
 Det forutsettes at forskningsdata oppbevares forskriftsmessig. 
Godkjennelsen gjelder til 15.8.2013.
Prosjektleder skal sende sluttmelding i henhold til helseforskningsloven § 12.
 Komiteens vedtak kan påklages til Den nasjonale forskningsetiske komité for medisin og helsefag, jf.





Vi ber om at alle henvendelser sendes inn via vår saksportal:  eller på e-posthttp://helseforskning.etikkom.no
til: post@helseforskning.etikkom.no
Vennligst oppgi vårt referansenummer i korrespondansen.
Med vennlig hilsen, 
May Britt Rossvoll                               Øyvind Strømseth 
sekretariatsleder                                seniorrådgiver
 
Kopi til: vinjar.fonnebo@uit.no

